

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number  
**WO 2004/077060 A2**

(51) International Patent Classification<sup>7</sup>: **G01N 33/574**

(21) International Application Number:  
PCT/CA2004/000280

(22) International Filing Date: 26 February 2004 (26.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/451,382 27 February 2003 (27.02.2003) US

(71) Applicant (for all designated States except US): **MOUNT SINAI HOSPITAL** [CA/CA]; 600 University Avenue, Room 970, Toronto, Ontario M5G 1X5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DIAMANDIS, Eleftherios, P.** [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA). **PETRAKI, Constantina, D.** [GR/GR]; Department of Pathology, Evangelismos Hospital, Phedriadon 109, GR-113 64 Athens (GR).

(74) Agent: **KURDYDYK, Linda**; McCarthy Tetrault, 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower, Toronto Dominion Centre, Toronto, Ontario M5K 1E6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/077060 A2

(54) Title: ASSAY FOR DETECTION OF RENAL CELL CARCINOMA

(57) Abstract: Methods for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

**TITLE: Assay for Detection of Renal Cell Carcinoma****FIELD OF THE INVENTION**

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating renal cell carcinoma.

**5 BACKGROUND OF THE INVENTION**

Kallikreins are a subgroup of secreted serine proteases, encoded by highly conserved and tightly clustered multigene families in humans, rats and mice. The human kallikrein gene family resides on chromosome 19q13.4 and is comprised of 15 members, whose genes are designated as *KLK1* to *KLK15* and the corresponding proteins as hK1 to hK15 (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204; Yousef GM, Chang A, Scorilas A, et al., *Biochem Biophys Res Commun*. 2000;276:125-133; Diamandis EP, 10 Yousef GM, Clements J, et al. *Clin Chem* .2000;46:1855-1858). Kallikreins are expressed in a wide variety of tissues and are found in many biological fluids (e.g. cerebrospinal fluid, serum, seminal plasma, milk, etc.) where they are predicted to process specific substrates. Kallikreins may participate in cascade reactions similar to those involved in digestion, fibrinolysis, coagulation, wound healing and apoptosis (Yousef GM, 15 Diamandis EP., *Endocr Rev* .2001;22:184-204). Many kallikreins have been found to be differentially expressed in endocrine-related malignancies (Diamandis EP, Yousef GM, *Expert Rev. Mol. Diagn* .2001;1:182-190), including prostate (Barry MJ. Clinical practice, *N Engl J Med* .2001;344:1373-1377; Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al., *Crit Rev Clin Lab Sci* .1998;35:275-368; and Yousef GM, Scorilas A, Jung K, et al., *J Biol Chem* .2001;276:53-61), ovarian (Kim H, Scorilas A, Katsaros D, et al., 20 *Br J Cancer*, 2001;84:643-650; Anisowicz A, Sotiropoulou G, Stenman, et al., *Mol Med* .1996;2:624-636; Tanimoto H, Underwood LJ, Shigemasa K, et al., *Cancer* .1999;86:2074-2082; Magklara A, Scorilas A, Katsaros D, et al., *Clin Cancer Res* .2001;7:806-811; Yousef GM, Kyriakopoulou LG, Scorilas A, et al., *Cancer Res* .2001;61:7811-7818; Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118), breast (Yousef GM, Magklara A, Chang A, et al., *Cancer Res* .2001;61:3425- 25 3431; Yousef GM, Chang A, Diamandis EP; *J Biol Chem* .2000;275:11891-11898; and Yousef GM, Magklara A, Diamandis EP, *Genomics* .2000;69:331-341), and testicular cancer (Luo LY, Rajpert-De Meyts ER, Jung K, et al., 2001;85:220-224). In addition, many kallikrein genes examined thus far are under steroid hormone regulation, implicating a role for kallikreins in endocrine-related tissues (Yousef GM, Diamandis EP., *Endocr Rev.*, 2001;22:184-204). Furthermore, hK6, hK10 and hK11 have been recently identified as 30 novel serological ovarian cancer biomarkers (Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118 Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P., *Clin Biochem*. 2000;33:579-583, and Diamandis EP, Okui A, Mitsui S, et al., *Cancer Res* .2002;62:295-300).

**SUMMARY OF THE INVENTION**

The present invention seeks to overcome the drawbacks inherent in the prior art and provide 35 sensitive and accurate methods for the detection of renal cell carcinoma. It has been found that one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and polynucleotides encoding the polypeptides, have particular application in the detection of renal cell carcinoma. Thus, the kallikrein markers constitute biomarkers for the diagnosis, monitoring, progression, treatment, and prognosis of renal cell carcinoma, and they may be used as biomarkers before

- 2 -

surgery or after relapse.

In accordance with the methods of the invention, the presence of levels of kallikrein markers in a sample can be assessed, for example by detecting the presence in the sample of (a) polypeptides or polypeptide fragments corresponding to the markers; (b) metabolites which are produced directly or indirectly by polypeptides corresponding to the markers; (c) transcribed nucleic acids or fragments thereof having at least a portion with which the markers are substantially identical; and/or (c) transcribed nucleic acids or fragments thereof, wherein the nucleic acids hybridize with the markers.

In an embodiment, the invention provides a method for detecting one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma in a patient comprising:

- (a) obtaining a sample from a patient;
- (b) detecting or identifying in the sample one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (c) comparing the detected amounts with amounts detected for a standard.

The term "detect" or "detecting" includes assaying, assessing, imaging or otherwise establishing the presence or absence of the target kallikrein polypeptides or polynucleotides encoding the polypeptides, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of renal cell carcinoma, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications. The kallikrein markers can be detected individually, sequentially, or simultaneously.

According to a method involving one or more kallikrein polypeptides the levels in the sample of one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma, are compared with the normal levels of the kallikrein polypeptides, in samples of the same type obtained from controls (e.g. samples from individuals not afflicted with renal cell carcinoma). Significantly different levels in the sample of the kallikrein polypeptides relative to the normal levels in a control is indicative of renal cell carcinoma.

In an embodiment, the invention provides a method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. The kallikrein markers can be detected using antibodies that bind to the kallikrein markers or parts thereof.

Thus, the invention provides a method of assessing whether a patient is afflicted with or has a pre-disposition for renal cell carcinoma, the method comprising comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

- 3 -

- 5 (b) normal levels of the kallikrein polypeptides, in samples of the same type obtained from control patients not afflicted with renal cell carcinoma, wherein significantly different levels of the kallikrein polypeptides, relative to the corresponding normal levels of the kallikrein polypeptides, is an indication that the patient is afflicted with renal cell carcinoma.

In an embodiment of a method of assessing whether a patient is afflicted with renal cell carcinoma (e.g. screening, detection of a recurrence, reflex testing), the method comprises comparing:

- 10 (a) levels of one or more, preferably 2 or more, kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides, in a control non-renal cell carcinoma sample.

A significant difference between the levels of the kallikrein polypeptides in the patient sample and the normal levels is an indication that the patient is afflicted with renal cell carcinoma. In an embodiment, the levels of kallikrein markers are significantly higher and are indicative of tumors of high grade, advanced stage disease, and/or lower survival.

15

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient. This method comprises comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- 20 (b) levels of the kallikrein polypeptides in a second sample obtained from the patient following therapy.

A significant difference between the levels of the kallikrein polypeptides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma.

25

The "therapy" may be any therapy for treating renal cell carcinoma including but not limited to chemotherapy, immunotherapy, gene therapy, radiation therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy, for example, to evaluate the reduction in tumor burden.

30 In an aspect, the invention provides a method for monitoring the progression of renal cell carcinoma in a patient, the method comprising:

- (a) detecting in a patient sample at a first time point, one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- 35 (b) repeating step (a) at a subsequent point in time; and
- (c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of renal cell carcinoma in the patient.

In another aspect, the invention provides a method for assessing the aggressiveness or indolence of renal cell carcinoma (e.g. staging), the method comprising comparing:

- 4 -

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides in a control sample.

5 A significant difference between the levels in the sample and the normal levels is an indication that the cancer is aggressive or indolent.

The invention provides a method for determining whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing:

- 10 (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels (or non-metastatic levels) of the kallikrein polypeptides in a control sample.

A significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

15 The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, and a method of selecting an agent for inhibiting renal cell carcinoma in a patient.

The invention further provides a method of inhibiting renal cell carcinoma in a patient comprising:

- 20 (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing levels of one or more kallikrein polypeptides, in each of the aliquots, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma;
- 25 (d) administering to the patient at least one of the test agents which alters the levels of the kallikrein polypeptides in the aliquot containing that test agent, relative to other test agents.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- 30 (b) comparing levels of kallikrein polypeptides in each of the aliquots, wherein the polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the kallikrein polypeptides in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

35 In embodiments of the methods of the invention, two, three, or four kallikrein polypeptides are employed. In preferred embodiments, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10; kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. In a particular embodiment, the kallikrein polypeptides are selected from the group consisting of kallikrein 6, kallikrein 10, and kallikrein 11.

- 5 -

Other methods of the invention employ one or more polynucleotides capable of hybridizing to polynucleotides encoding kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. Methods for detecting polynucleotides encoding kallikrein polypeptides can be used to monitor renal cell carcinoma by detecting the nucleic acids.

Thus, the present invention relates to a method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting polynucleotides encoding kallikrein polypeptides in the sample, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The presence of different levels of polynucleotides encoding the kallikrein polypeptides, in the sample compared to a standard or control is indicative of disease, disease stage, and/or prognosis, e.g. progression-free and overall survival.

In an embodiment, the invention provides methods for determining the presence or absence of renal cell carcinoma in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject. Within certain embodiments, mRNA is detected via polymerase chain reaction using, for example oligonucleotide primers that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids.

When using mRNA detection, the method may be carried out by combining isolated mRNA with reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of polynucleotides encoding kallikrein polypeptides in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of polynucleotides encoding kallikrein polypeptides. The analysis step may be further accomplished by quantitatively detecting the presence of polynucleotides encoding kallikrein polypeptides in the amplification product, and comparing the quantity of markers detected against a panel of expected values for the known presence or absence of the markers in normal and malignant tissue derived using similar primers.

In embodiments of the invention, one, two, three or four polynucleotides encoding kallikrein polypeptides are employed. In preferred embodiments, the polynucleotides encode kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and kallikrein 6, kallikrein 10 and kallikrein 11.

The invention also provides a diagnostic composition comprising kallikrein polypeptides, or polynucleotides encoding the polypeptides, or agents that bind to the polypeptides or nucleic acids.

In an embodiment, the composition comprises probes that specifically hybridize to polynucleotides

- 6 -

encoding kallikrein polypeptides, or fragments thereof. In another embodiment a composition is provided comprising specific primer pairs capable of amplifying polynucleotides encoding kallikrein polypeptides, using polymerase chain reaction methodologies. In a still further embodiment, the composition comprises agents that bind to kallikrein polypeptides (e.g. antibodies) or fragments thereof. Probes, primers, and agents  
5 can be labeled with detectable substances.

In an aspect the invention provides an *in vivo* method comprising administering to a subject agents that have been constructed to target kallikrein polypeptides.

The invention therefore contemplates an *in vivo* method comprising administering to a mammal imaging agents that carry labels for imaging and that bind to kallikrein polypeptides, and then imaging the  
10 mammal.

Still further the invention relates to therapeutic applications for renal cell carcinoma employing kallikrein polypeptides and polynucleotides encoding the polypeptides, and/or agents identified using methods of the invention.

The invention also includes kits for carrying out methods of the invention. In an embodiment, the  
15 kit is for assessing whether a patient is afflicted with renal cell carcinoma and it comprises reagents for assessing one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

In another aspect the invention relates to a kit for assessing the suitability of each of a plurality of test compounds for inhibiting renal cell carcinoma in a patient. The kit comprises reagents for assessing  
20 kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The kit may also comprise a plurality of test agents or compounds.

The invention contemplates a kit for assessing the presence of renal cell carcinoma cells, wherein the kit comprises antibodies specific for selected markers, wherein the markers comprise or are selected from  
25 the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

Additionally the invention provides a kit for assessing the renal cell carcinoma carcinogenic potential of a test compound. The kit comprises renal cell carcinoma cells and reagents for assessing kallikrein markers, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

30 In an aspect the invention provides a method of treating a patient afflicted with renal cell carcinoma comprising providing to cells of a patient antisense oligonucleotides complementary to polynucleotides encoding one or more kallikrein polypeptides, which are overexpressed in renal cell carcinoma. In an alternative method, expression of genes corresponding to one or more kallikrein polypeptides which are underexpressed in renal cell carcinoma are increased.

35 The invention relates to a method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma comprising inhibiting or increasing expression (or overexpression) of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, that are either overexpressed or underexpressed, in renal cell carcinoma.

- 7 -

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The invention relates to newly discovered correlations between expression of certain markers and renal cell carcinoma. The combinations of markers described herein may provide sensitive methods for detecting renal cell carcinoma. The levels of expression of a combination of markers described herein may correlate with the presence of renal cell carcinoma or a pre-malignant condition in a patient. Methods are provided for detecting the presence of renal cell carcinoma in a sample, the absence of renal cell carcinoma in a sample, the stage of a renal cell carcinoma, the grade of a renal cell carcinoma, the benign or malignant nature of a renal cell carcinoma, the metastatic potential of a renal cell carcinoma, assessing the histological type of neoplasm associated with the renal cell carcinoma, the indolence or aggressiveness of the cancer, and other characteristics of renal cell carcinoma that are relevant to prevention, diagnosis, characterization, and therapy of renal cell carcinoma in a patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting renal cell carcinoma, assessing the efficacy of a therapy for renal cell carcinoma, monitoring the progression of renal cell carcinoma, selecting an agent or therapy for inhibiting renal cell carcinoma, treating a patient afflicted with renal cell carcinoma, inhibiting renal cell carcinoma in a patient, and assessing the carcinogenic potential of a test compound.

#### **Glossary**

The terms "sample", "biological sample", and the like, mean a material known or suspected of expressing or containing kallikrein polypeptides associated with renal cell carcinoma, or polynucleotides encoding the polypeptides. The test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like. Nucleic acids and polypeptides may be isolated from the samples and utilized in the methods of the invention. In a preferred embodiment, the sample is a serum sample.

The term "subject" or "patient" refers to a warm-blooded animal such as a mammal, which is suspected of having renal cell carcinoma or a condition, disease, or syndrome associated with renal cell carcinoma. Preferably, "subject" refers to a human.

"Kallikrein polypeptides" or "kallikrein markers" include one or more of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The amino acid sequences for native kallikrein polypeptides employed in the



- 8 -

present invention include the sequences found in GenBank for each polypeptide as shown in Table 1, and in SEQ ID NO: 1 (kallikrein 5), NO. 4 (kallikrein 6), NO. 8 (kallikrein 10), and NOs. 11 and 12 (kallikrein 11), or a portion thereof. Other useful polypeptides are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity), and preferably retain the immunogenic activity of the corresponding native-sequence kallikrein polypeptide.

A "native-sequence polypeptide" comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

The term "native-sequence polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants.

The term "polypeptide variant" means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in the GenBank Accession Nos. in Table 1 and shown in SEQ ID NOS 1, 4, 8, 11, and 12. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOS: 1, 4, 8, 11, and 12, including variants from other species, but excludes a native-sequence polypeptide.

An allelic variant may also be created by introducing substitutions, additions, or deletions into a nucleic acid encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

- 9 -

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a kallikrein polypeptide homolog, for example, the murine kallikrein polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a kallikrein polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., *Nucleic Acids Research* 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. *J. Molec. Biol.* 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. *J. Mol. Biol.* 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

Kallikrein polypeptides include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a kallikrein polypeptide operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same kallikrein polypeptide). Within the fusion protein, the term "operably linked" is intended to indicate that the kallikrein polypeptide and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the kallikrein polypeptide. A useful fusion protein is a GST fusion protein in which a kallikrein polypeptide is fused to the C-terminus of GST sequences. Another example of a fusion protein is an immunoglobulin fusion protein in which all or part of a kallikrein polypeptide is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

Kallikrein polypeptides may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

"Kallikrein polynucleotides" or "polynucleotides encoding kallikrein polypeptides" refers to one or more of kallikrein 5 polynucleotide (KLK5), kallikrein 6 polynucleotide (KLK6), kallikrein 10 polynucleotide (KLK10), and kallikrein 11 polynucleotide (KLK11). The term includes polynucleotides that encode a native-sequence polypeptide, a polypeptide variant including a portion of a kallikrein polypeptide, an isoform, precursor, and chimeric polypeptide.

The polynucleotide sequences encoding native kallikrein polypeptides employed in the present invention include the nucleic acid sequences of the GenBank Accession Nos. identified in Table 1, and in SEQ ID NOs: 2 and 3 (KLK5), NOs. 5, 6, and 7 (KLK6), NOs. 9 and 10 (KLK10), and NOs. 13 and 14 (KLK11), or a fragment thereof.

Polynucleotides encoding kallikrein polypeptides include nucleic acid sequences complementary to these nucleic acids, and polynucleotides that are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity).

5 Kallikrein polynucleotides also include sequences which differ from a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14, due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a kallikrein polypeptide may result in silent mutations that do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to  
10 natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a kallikrein polypeptide.

Kallikrein polynucleotides also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14. Appropriate stringency conditions which  
15 promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In  
20 addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Kallikrein polynucleotides also include truncated nucleic acids or nucleic acid fragments and variant forms of the nucleic acids that arise by alternative splicing of an mRNA corresponding to a DNA.

Kallikrein polynucleotides are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-  
25 coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method.

One or more kallikrein polypeptides or kallikrein polynucleotides are detected in the present invention. In an aspect, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10;  
30 kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10 and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11. In another aspect, the kallikrein polynucleotides comprise KLK6; KLK6 and KLK10; KLK6 and KLK11; KLK6, KLK10 and KLK11; or KLK5, KLK6, KLK10 and KLK11

#### General Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of renal cell  
35 carcinoma involving kallikrein polypeptides, and polynucleotides encoding the polypeptides, and the identification of subjects with a predisposition to such disorders. Such methods may, for example, utilize polynucleotides encoding kallikrein polypeptides, and fragments thereof, and binding agents (e.g. antibodies aptamers) against kallikrein polypeptides, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of either over- or under-expression of kallikrein

polynucleotides, relative to a non-disorder state; and (2) the detection of either an over- or an under-abundance of kallikrein polypeptides, relative to a non-disorder state or the presence of modified (e.g., less than full length) kallikrein polypeptides that correlate with a disorder state, or a progression toward a disorder state.

5           The invention also contemplates a method for detecting renal cell carcinoma comprising producing a profile of levels of kallikrein polypeptides in cells from a patient, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and/or kallikrein 11, and comparing the profile with a reference to identify a protein profile for the test cells indicative of disease.

10           The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

15           The methods described herein can be adapted for diagnosing and monitoring renal cell carcinoma by detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in biological samples from a subject. These applications require that the amount of polypeptides or polynucleotides quantitated in a sample from a subject being tested be compared to a predetermined standard. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a control sample. Levels for control samples from healthy subjects or renal cell carcinoma subjects may be established by prospective and/or retrospective statistical studies. Healthy or normal subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of kallikrein polypeptides, or polynucleotides encoding same, compared to a control sample or previous levels quantitated for the same subject. A "significant difference" 25 in levels of markers or polynucleotides in a patient sample compared to a control or standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay, preferably the levels are at least about 1.5, 2, 3, 4, 5, or 6 times higher or lower, respectively, than the control or standard. The difference in levels of markers or polynucleotides may be a statistically significant difference.

30           In an embodiment, the levels of kallikrein markers, in particular kallikrein 6 and kallikrein 10, are significantly higher in subjects with renal cell carcinoma, more particularly renal cell carcinoma with tumors of high grade and/or advanced stage. In another embodiment, there is a statistically significant difference in kallikrein 6 levels and/or kallikrein 10 levels which are indicative of late stage disease and/or reduced disease survival.

35           **Nucleic Acid Methods/Assays**

As noted herein renal cell carcinoma may be detected based on the level of polynucleotides encoding kallikrein polypeptides in a sample. Techniques for detecting nucleic acid molecules such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

- 12 -

Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of polynucleotides encoding kallikrein polypeptides, preferably they comprise 15 to 40 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$  or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect polynucleotides encoding kallikrein polypeptides preferably in human cells. The nucleotide probes may also be useful in the diagnosis of renal cell carcinoma involving polynucleotides encoding kallikrein polypeptides, in monitoring the progression of such disorder, or monitoring a therapeutic treatment.

Probes may be used in hybridization techniques to detect polynucleotides encoding kallikrein polypeptides. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with probes under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

The detection of polynucleotides encoding kallikrein polypeptides, may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

By way of example, oligonucleotide primers may be employed in a PCR based assay to amplify a portion of polynucleotides encoding kallikrein polypeptides, derived from a sample, wherein the oligonucleotide primers are specific for (i.e. hybridize to) polynucleotides encoding each of the kallikrein polypeptides. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75% and more preferably at least about 90% identity to a portion of polynucleotides encoding kallikrein polypeptides. The primers and probes may be at least 10 nucleotides, and preferably at least 20 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of expression of polynucleotides encoding kallikrein polypeptides. For example, RNA may be isolated from a cell type or tissue known to express these polynucleotides and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomcynski and Sacchi, Anal. Biochem. 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to sets of primers specifically designed against a kallikrein polynucleotide sequence. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with suspected renal cell carcinoma and an individual who is not afflicted with renal cell carcinoma. The reaction may be performed on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-cancerous sample may be considered positive for the presence of renal cell carcinoma.

Oligonucleotides or longer fragments derived from polynucleotides encoding each kallikrein polypeptide may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes. The information from the microarray may be used to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

Thus the invention also includes an array comprising polynucleotides encoding kallikrein marker(s). The array can be used to assay expression of kallikrein polynucleotides in the array. The invention allows the quantitation of expression of polynucleotides encoding kallikrein markers.

In an embodiment, the array can be used to monitor the time course of expression of kallikrein polynucleotides in the array. This can occur in various biological contexts such as tumor progression.

The array is also useful for ascertaining differential expression patterns of kallikrein polynucleotides in normal and abnormal cells. This provides a battery of polynucleotides that could serve as molecular targets for diagnosis or therapeutic intervention.

#### **Protein Methods**

Binding agents specific for kallikrein polypeptides may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an renal cell

carcinoma in a subject may be determined by (a) contacting a sample from the subject with binding agents for kallikrein polypeptides; (b) detecting in the sample levels of polypeptides that bind to the binding agents; and (c) comparing the levels of polypeptides with a predetermined standard or cut-off value.

"Binding agent" refers to a substance such as a polypeptide or antibody that specifically binds to a kallikrein polypeptide. A substance "specifically binds" to a polypeptide if it reacts at a detectable level with the kallikrein polypeptide, and does not react detectably with peptides containing unrelated sequences or sequences of different polypeptides. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al, Develop. Dynamics 197: 1-13, 1993).

A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises a kallikrein polypeptide sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example a kallikrein polypeptide sequence may be a peptide portion of a kallikrein polypeptide that is capable of modulating a function mediated by the kallikrein polypeptide.

An aptamer includes a DNA or RNA molecule that binds to polynucleotides and polypeptides. An aptamer that binds to a polypeptide (or binding domain) of a kallikrein polypeptide or a polynucleotide encoding a kallikrein polypeptide can be produced using conventional techniques, without undue experimentation. [For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)].

In certain other preferred embodiments, the binding agent is an antibody.

In an aspect the present invention provides a diagnostic method for monitoring or diagnosing renal cell carcinoma in a subject by quantitating kallikrein polypeptides, in a biological sample from the subject comprising reacting the sample with antibodies specific for kallikrein polypeptides, which are directly or indirectly labelled with detectable substances, and detecting the detectable substances.

In an aspect of the invention, a method for detecting renal cell carcinoma is provided comprising:

- (a) obtaining a sample suspected of containing kallikrein polypeptides associated with renal cell carcinoma, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) contacting the sample with antibodies that specifically bind kallikrein polypeptides, under conditions effective to bind the antibodies and form complexes;
- (c) measuring the amount of kallikrein polypeptides, present in the sample by quantitating the amount of the complexes; and
- (d) comparing the amount of kallikrein polypeptides, present in the samples with the amount of polypeptides in a control, wherein a change or significant difference in the amount of polypeptides in the sample compared with the amount in the control is indicative of renal cell carcinoma.

- 15 -

In an embodiment, the invention contemplates a method for monitoring the progression of renal cell carcinoma in an individual, comprising:

- (a) contacting antibodies which bind to kallikrein polypeptides, with a sample from the individual so as to form binary complexes comprising each of the antibodies and polypeptides in the sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) determining or detecting the presence or amount of complex formation in the sample;
- (c) repeating steps (a) and (b) at a point later in time; and
- (d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of the stage and/or progression of the renal cell carcinoma in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, renal cell carcinoma at different stages.

Thus, antibodies specifically reactive with a kallikrein polypeptide, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect a kallikrein polypeptide, in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the levels of expression of kallikrein polypeptides, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of kallikrein polypeptides. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on renal cell carcinoma involving kallikrein polypeptides, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of kallikrein polypeptides, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect kallikrein polypeptides, to localize them to particular renal cell carcinoma tumor cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or (Fab)<sub>2</sub> fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F<sub>v</sub> molecules (Ladner et al, U.S. Pat. No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant kallikrein



- 16 -

polypeptides may be utilized to prepare antibodies. See, for example, Kohler et al. (1975) *Nature* 256:495-497; Kozbor et al. (1985) *J. Immunol Methods* 81:31-42; Cote et al. (1983) *Proc Natl Acad Sci* 80:2026-2030; and Cole et al. (1984) *Mol Cell Biol* 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) *Science* 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) *Immunochemical Protocols*, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies. The antibodies specific for kallikrein polypeptides used in the methods of the invention may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against kallikrein polypeptides if they bind with a  $K_a$  of greater than or equal to  $10^{-7}$  M.

Antibodies that bind to kallikrein polypeptides may be labelled with a detectable substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g.,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a kallikrein polypeptide. The second antibody may be labeled with a detectable substance to detect the primary antigen-antibody reaction. By way of example, if the antibody having specificity against a kallikrein polypeptide is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect kallikrein polypeptides. Generally, antibodies may be labeled with detectable substances and kallikrein polypeptides, may be localised in tissues and cells based upon the presence of the detectable substance.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies) for kallikrein polypeptides may be immobilized on a carrier or support. Examples of suitable carriers or

supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized material may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. Binding agents (e.g. antibodies) may be indirectly immobilized using second binding agents specific for the first binding agent. For example, mouse antibodies specific for a kallikrein polypeptide may be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where radioactive labels are used as a detectable substance, kallikrein polypeptides may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

Therefore, in accordance with an embodiment of the invention, a method is provided wherein antibodies specific for each kallikrein polypeptide, are labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of the enzymes and substrates, form fluorescent complexes with lanthanide metals. Lanthanide metals are added and the kallikrein polypeptides are quantitated in the sample by measuring fluorescence of the fluorescent complexes. Antibodies specific for the kallikrein polypeptides may be directly or indirectly labelled with enzymes. Enzymes are selected based on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Examples of suitable enzymes include alkaline phosphatase and  $\beta$ -galactosidase.

Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

Antibodies specific for kallikrein polypeptides may also be indirectly labelled with enzymes. For example, an antibody may be conjugated to one partner of a ligand binding pair, and the enzyme may be coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In another embodiment, antibodies specific for the anti-kallikrein antibodies are labeled with an enzyme.

In accordance with an embodiment, the present invention provides means for determining kallikrein polypeptides in a sample, in particular a serum sample, by measuring kallikrein polypeptides by

immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure kallikrein polypeptides in serum. In general, an immunoassay method may be competitive or noncompetitive. Competitive methods typically employ immobilized or immobilizable antibodies to the kallikrein polypeptides and a labeled form of each of the kallikrein polypeptides. Kallikrein polypeptides and  
5 labeled kallikrein polypeptides compete for binding to anti-kallikrein antibodies. After separation of the resulting labeled kallikrein polypeptides that have become bound to anti-kallikrein polypeptides (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the amount of kallikrein polypeptides, in the test sample in any conventional manner, e.g., by comparison to a standard curve.

10 In an aspect, a non-competitive method is used for the determination of kallikrein polypeptides with the most common method being the "sandwich" method. In this assay, two types of antibodies specific for kallikrein polypeptides are employed. One type of antibody is directly or indirectly labeled (sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or  
15 sequentially with a test sample. Sequential methods can be accomplished by incubating capture antibodies with the sample, and adding the detection antibodies at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibodies can be incubated with the sample first and then the capture antibodies added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to complete the assay, the capture antibodies are separated from the liquid test mixture, and  
20 labels are measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally the labels are measured in the capture antibody phase since it comprises kallikrein polypeptides bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

In a typical two-site immunometric assay for kallikrein polypeptides, one or both of the capture and  
25 detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The labels used with the detection antibodies can be selected from any of those known conventionally in the art. The labels may be an enzyme or a chemiluminescent moiety, but it can also be a radioactive isotope, a fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the  
30 ligand), and the like. Preferably antibodies are labelled with enzymes which are detected by adding substrates that are selected so that a reaction product of the enzymes and substrates forms fluorescent complexes. Capture antibodies may be selected so that they provide a means for being separated from the remainder of the test mixture. Accordingly, the capture antibodies can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables  
35 immobilization to be accomplished subsequent to introduction of the capture antibodies to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by

contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, a capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

5 A particular sandwich immunoassay method of the invention employs two types of antibodies, first antibodies are reactive against kallikrein polypeptides and second antibodies having specificity against antibodies reactive against kallikrein polypeptides labelled with enzymatic labels, and fluorogenic substrates for the enzymes. An enzyme may be alkaline phosphatase (ALP) and the substrate is 5-fluorosalicyl phosphate. ALP cleaves phosphate out of the fluorogenic substrate, 5-fluorosalicyl phosphate, to produce 5-fluorosalicylic acid (FSA). 5-Fluorosalicylic acid can then form a highly fluorescent ternary complex of the  
10 form FSA-Tb(3+)-EDTA, which can be quantified by measuring the Tb3+ fluorescence in a time-resolved mode. Fluorescence intensity is measured using a time-resolved fluorometer as described herein.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

#### Computer Systems

15 Computer readable media comprising kallikrein markers is also provided. "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the invention contemplates computer readable  
20 medium having recorded thereon markers identified for patients and controls.

"Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on kallikrein markers.

A variety of data processor programs and formats can be used to store information on kallikrein  
25 markers on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

30 By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

The invention provides a medium for holding instructions for performing a method for determining  
35 whether a patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

- 20 -

The invention also provides in an electronic system and/or in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention further provides in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring information from the network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information and information on the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention still further provides a system for identifying selected records that identify a renal cell carcinoma cell. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising kallikrein markers, or polynucleotides encoding same, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting a renal cell carcinoma cell using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

- (a) creating records of kallikrein markers or polynucleotides encoding same, isolated from a sample suspected of containing an renal cell carcinoma cell;
- (b) providing a database comprising records of data comprising kallikrein markers, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and/or comprising polynucleotides encoding same; and
- (c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a positive indication that the markers of step (a) have been isolated from a cell that is a renal cell carcinoma cell.

The invention contemplates a business method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring

information from a network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information, information on the kallikrein markers or polynucleotides encoding same, and acquired information, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

#### Imaging Methods

Antibodies specific for kallikrein polypeptides may also be used in imaging methodologies in the management of renal cell carcinoma. The invention provides a method for imaging tumors associated with kallikrein polypeptides.

In an embodiment the method is an *in vivo* method and a subject or patient is administered imaging agents that carry imaging labels and are capable of targeting or binding to kallikrein polypeptides. In the method each imaging agent is labeled so that it can be distinguished during the imaging. The imaging agents are allowed to incubate *in vivo* and bind to the kallikrein polypeptides associated with renal cell carcinoma tumors. The presence of label is localized to the renal cell carcinoma, and the localized label is detected using imaging devices known to those skilled in the art.

The imaging agents may be antibodies or chemical entities that recognize kallikrein polypeptides. In an aspect of the invention an imaging agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for kallikrein polypeptides used in the methods of the invention may be obtained from scientific or commercial sources, or isolated native or recombinant kallikrein polypeptides may be utilized to prepare antibodies etc as described herein.

An imaging agent may be a peptide that mimics the epitope for an antibody specific for a kallikrein polypeptide and binds to a kallikrein polypeptide. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes tyrosine, lysine, or phenylalanine to which  $N_2S_2$  chelate is complexed (See U.S. Patent No. 4,897,255). The anti-kallikrein peptide conjugate is then combined with a radiolabel (e.g. sodium  $^{99m}Tc$  pertechnetate or sodium  $^{188}Re$  perrhenate) and it may be used to locate a tumor producing the kallikrein polypeptides.

Imaging agents carry labels to image the kallikrein polypeptides. Agents may be labelled for use in radionuclide imaging. In particular, agents may be directly or indirectly labelled with a radioisotope. Examples of radioisotopes that may be used in the present invention are the following:  $^{277}Ac$ ,  $^{211}At$ ,  $^{128}Ba$ ,  $^{131}Ba$ ,  $^7Be$ ,  $^{204}Bi$ ,  $^{205}Bi$ ,  $^{206}Bi$ ,  $^{76}Br$ ,  $^{77}Br$ ,  $^{82}Br$ ,  $^{109}Cd$ ,  $^{47}Ca$ ,  $^{11}C$ ,  $^{14}C$ ,  $^{36}Cl$ ,  $^{48}Cr$ ,  $^{51}Cr$ ,  $^{62}Cu$ ,  $^{64}Cu$ ,  $^{67}Cu$ ,  $^{165}Dy$ ,  $^{155}Eu$ ,  $^{18}F$ ,  $^{153}Gd$ ,  $^{66}Ga$ ,  $^{67}Ga$ ,  $^{68}Ga$ ,  $^{72}Ga$ ,  $^{198}Au$ ,  $^3H$ ,  $^{166}Ho$ ,  $^{111}In$ ,  $^{113m}In$ ,  $^{115m}In$ ,  $^{123}I$ ,  $^{125}I$ ,  $^{131}I$ ,  $^{189}Ir$ ,  $^{191m}Ir$ ,  $^{192}Ir$ ,  $^{194}Ir$ ,  $^{52}Fe$ ,  $^{55}Fe$ ,  $^{59}Fe$ ,  $^{177}Lu$ ,  $^{15}O$ ,  $^{191m-191}Os$ ,  $^{109}Pd$ ,  $^{32}P$ ,  $^{33}P$ ,  $^{42}K$ ,  $^{226}Ra$ ,  $^{186}Re$ ,  $^{188}Re$ ,  $^{82m}Rb$ ,  $^{153}Sm$ ,  $^{46}Sc$ ,  $^{47}Sc$ ,  $^{72}Se$ ,  $^{75}Se$ ,  $^{105}Ag$ ,  $^{22}Na$ ,  $^{24}Na$ ,  $^{89}Sr$ ,  $^{35}S$ ,  $^{38}S$ ,  $^{177}Ta$ ,  $^{96}Tc$ ,  $^{99m}Tc$ ,  $^{201}Tl$ ,  $^{202}Tl$ ,  $^{113}Sn$ ,  $^{117m}Sn$ ,  $^{121}Sn$ ,  $^{166}Yb$ ,  $^{169}Yb$ ,  $^{175}Yb$ ,  $^{88}Y$ ,  $^{90}Y$ ,  $^{62}Zn$  and  $^{65}Zn$ . Preferably the radioisotope is  $^{131}I$ ,  $^{125}I$ ,  $^{123}I$ ,  $^{111}I$ ,  $^{99m}Tc$ ,  $^{90}Y$ ,  $^{186}Re$ ,  $^{188}Re$ ,  $^{32}P$ ,  $^{153}Sm$ ,  $^{67}Ga$ ,  $^{201}Tl$ ,  $^{77}Br$ , or  $^{18}F$ , and it is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling,

and  $^{35}\text{S}$  labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, Nature 144:945 (1962), David et al., Biochemistry 13:1014-1021 (1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., Biochem. J. 89:114-123 (1963); Marchalonis, J., Biochem. J. 113:299-305 (1969); and Morrison, M. et al., Immunochemistry, 289-297 (1971).  $^{99\text{m}}\text{Tc}$ -labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S. Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for  $^{111}\text{In}$ -labeling biological agents are described by Hnatowich, D. J. et al., J. Immunol. Methods, 65:147-157 (1983), Hnatowich, D. et al., J. Applied Radiation, 35:554-557 (1984), and Buckley, R. G. et al., F.E.B.S. 166:202-204 (1984).

An imaging agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo* method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

In the case of radiolabeled agents, the agents may be administered to the patient, localized to the tumor having one or more kallikrein polypeptides with which the agents bind, and detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using, for example, a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g.,  $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{15}\text{O}$ , and  $^{13}\text{N}$ ).

Whole body imaging techniques using radioisotope labeled agents can be used for locating both primary tumors and tumors which have metastasized. Antibodies specific for kallikrein polypeptides or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For renal cell carcinoma, administration preferably is intravenous. The bio-distribution of the labels can be monitored by scintigraphy, and accumulations of the labels can be related to the presence of renal cell carcinoma cells. Whole body imaging techniques are described in U.S. Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis, staging and visualization of cancer, in particular renal cell carcinoma, so that surgical and/or radiation treatment protocols can be used more efficiently.

**Screening Methods**

The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit renal cell carcinoma or potentially contribute to renal cell carcinoma. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)<sub>2</sub>, and Fab expression library fragments, and epitope-binding fragments thereof)], nucleic acids (e.g. antisense, interference RNA) and small organic or inorganic molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing:

- (a) levels of kallikrein markers or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and
- (b) levels of the kallikrein markers or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of kallikrein markers or polynucleotides encoding same in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

In an aspect, the invention provides a method of selecting an agent for inhibiting renal cell carcinoma in a patient comprising:

- (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing kallikrein markers and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
- (d) selecting one of the test agents which alters the levels of the kallikrein markers and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery business comprising:

- (a) providing one or more methods or assay systems for identifying agents that inhibit renal cell carcinoma in a patient;
- (b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and



- 24 -

- (c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as having an acceptable therapeutic profile.

In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- (b) comparing kallikrein markers and/or polynucleotides encoding same in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

#### Kits

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least kallikrein polynucleotides or binding agents (e.g. antibodies) described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients, and to screen and identify those individuals afflicted with or exhibiting a predisposition to renal cell carcinoma.

Thus, the invention also contemplates kits for carrying out the methods of the invention. Such kits typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

In an embodiment, a container with a kit comprises binding agents as described herein. By way of example, the kit may contain antibodies specific for kallikrein polypeptides, antibodies against the antibodies labelled with enzymes, and substrates for the enzymes. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

In an aspect of the invention, the kit includes antibodies or antibody fragments which bind specifically to epitopes of kallikrein polypeptides, and means for detecting binding of the antibodies to epitopes associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents. Containers that provide a formulation for direct use, usually do not require other reagents, as for example, where the kit contains radiolabelled antibody preparations for *in vivo* imaging.

A kit may be designed to detect the level of polynucleotides encoding kallikrein polypeptides in a sample. Such kits generally comprise oligonucleotide probes or primers, as described herein, that hybridize to polynucleotides encoding kallikrein polypeptides. Such oligonucleotides may be used, for example, within

- 25 -

a PCR or hybridization procedure. Additional components that may be present within the kits include second oligonucleotides and/or diagnostic reagents to facilitate detection of polynucleotides encoding kallikrein polypeptides.

5 The reagents suitable for applying the screening methods of the invention to evaluate compounds may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

#### Applications

10 Kallikrein polypeptides are targets for renal cell carcinoma immunotherapy. Such immunotherapeutic methods include the use of antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

In one aspect, the invention provides antibodies specific for kallikrein polypeptides that may be used systemically to treat renal cell carcinoma. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue. Thus, the invention provides a method of treating a patient susceptible to, or having a cancer that expresses kallikrein polypeptides comprising administering to the patient an effective amount of antibodies that bind specifically to kallikrein polypeptides. In another aspect, the invention provides a method of inhibiting the growth of tumor cells expressing kallikrein polypeptides, comprising administering to a patient antibodies which bind specifically to kallikrein polypeptides in amounts effective to inhibit growth of the tumor cells. Antibodies specific for kallikrein polypeptides may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing kallikrein polypeptides comprising reacting antibody immunoconjugates or immunotoxins with the cell in an amount sufficient to inhibit the growth of, or kill the cell.

By way of example, unconjugated antibodies specific for kallikrein polypeptides may be introduced into a patient such that the antibodies bind to cancer cells expressing kallikrein polypeptides and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, altering the physiologic function of kallikrein polypeptides and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies, antibodies specific for kallikrein polypeptides, conjugated to therapeutic agents (e.g. immunoconjugates) may also be used therapeutically to deliver the agents directly to tumor cells expressing kallikrein polypeptides and thereby destroy the tumor. Examples of such agents include abrin, ricin A, *Pseudomonas* exotoxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

35 Cancer immunotherapy using antibodies specific for kallikrein polypeptides may utilize the various approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlén et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunother Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54:

- 26 -

6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

In the practice of a method of the invention, antibodies specific for kallikrein polypeptides capable of inhibiting the growth of cancer cells expressing kallikrein polypeptides are administered in a therapeutically effective amount to cancer patients whose tumors express or overexpress kallikrein polypeptides. The invention may provide a specific, effective and long-needed treatment for renal cell carcinoma. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

Patients may be evaluated for the presence and levels of kallikrein polypeptides expression and overexpression in tumors, preferably using immunohistochemical assessments of tumor tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of kallikrein polypeptides. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

Antibodies specific for kallikrein polypeptides useful in treating cancer include those that are capable of initiating a potent immune response against the tumor and those that are capable of direct cytotoxicity. In this regard, the antibodies may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, antibodies specific for kallikrein polypeptides that exert a direct biological effect on tumor growth are useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

The anti-tumor activity of a combination of antibodies specific for kallikrein polypeptides may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, wherein human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

The methods of the invention contemplate the administration of combinations, or "cocktails" of different individual antibodies recognizing epitopes of kallikrein polypeptides. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects. In addition, the administration of the antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

- 27 -

The antibodies specific for kallikrein polypeptides used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the anti-tumor function of the antibodies and is non-reactive with the subject's immune systems. Examples  
5 include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16.sup.th Edition, A. Osal., Ed., 1980).

Antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Routes of administration include, but are not limited to, intravenous, intraperitoneal,  
10 intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

Treatment will generally involve the repeated administration of the antibody preparation via an acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will  
15 depend upon various factors generally appreciated by those of skill in the art, including the type of cancer and the severity, grade, or stage of the cancer, the binding affinity and half life of the antibodies used, the degree of expression of kallikrein polypeptides in the patient, the extent of circulating kallikrein polypeptide antigens the desired steady-state antibody concentration level, frequency of treatment, and the influence of  
20 any chemotherapeutic agents used in combination with a treatment method of the invention.

Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies per week may be effective and well tolerated, although even higher weekly doses may be appropriate and/or  
well tolerated. A determining factor in defining the appropriate dose is the amount of antibodies necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve  
25 tumor inhibition or regression. Direct administration of antibodies specific for kallikrein polypeptides is also possible and may have advantages in certain situations.

Patients may be evaluated for kallikrein polypeptides, preferably in serum, in order to assist in the determination of the most effective dosing regimen and related factors. The assay methods described herein, or similar assays, may be used for quantitating circulating kallikrein polypeptide levels in patients prior to  
30 treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters, such as serum kallikrein polypeptides.

The invention further provides vaccines formulated to contain kallikrein polypeptides or fragments thereof. The use in anti-cancer therapy of tumor antigens in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human  
35 PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These methods can be practiced by employing kallikrein polypeptides, or fragments thereof, or polynucleotides and recombinant vectors capable of expressing and appropriately presenting the kallikrein immunogens.

By way of example, viral gene delivery systems may be used to deliver polynucleotides encoding kallikrein polypeptides. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding kallikrein polypeptides, or fragments thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present kallikrein antigens to a patient's immune system. For example, autologous dendritic cells which express MHC class I and II, may be pulsed with kallikrein polypeptides, or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate renal cell carcinoma patients' immune systems (See, for example, Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380).

Anti-idiotypic antibodies specific for kallikrein polypeptides can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing the polypeptides. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic antibodies that mimic an epitope on a kallikrein polypeptide (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such antibodies can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing kallikrein polypeptides. Constructs comprising DNA encoding kallikrein polypeptides/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded kallikrein polypeptides/immunogens. The polypeptides/immunogens may be expressed as cell surface proteins or be secreted. Expression of the polypeptides/immunogens results in the generation of prophylactic or therapeutic humoral and cellular immunity against the cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing kallikrein polypeptides. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that the kallikrein polypeptides form a complex with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing kallikrein polypeptides by reacting a combination of the immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver polynucleotides encoding kallikrein polypeptides to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct

- 29 -

recombinant vectors that will express antisense nucleic acid molecules for kallikrein polypeptides. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Genes encoding kallikrein polypeptides can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired kallikrein polypeptide-encoding fragments. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of genes encoding kallikrein polypeptides, i.e., the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, e.g. between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding kallikrein polypeptides.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GGU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Kallikrein polypeptides and polynucleotides encoding the polypeptides, and fragments thereof, antibodies, and/or agents identified using a method of the invention, or combinations thereof, may be used in the treatment of renal cell carcinoma or diseases, conditions or syndromes associated with renal cell carcinoma, in a subject. The kallikrein polypeptides, polynucleotides, and agents may be formulated into compositions for administration to subjects suffering from renal cell carcinoma. Therefore, the present invention also relates to a composition comprising kallikrein polypeptides, or polynucleotides encoding the

- 30 -

polypeptides, or a fragment thereof, or an agent identified using a method of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing renal cell carcinoma in a subject is also provided comprising administering to a patient in need thereof, kallikrein polypeptides, or polynucleotides encoding the polypeptides, an agent identified in accordance with a method of the invention, or a composition of the invention.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the substance.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other therapeutic agents or other forms of treatment (e.g. chemotherapy or radiotherapy). The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The following non-limiting examples are illustrative of the present invention:

#### Example 1

Human kallikreins 5, 6, 10, and 11 (hK5/6/10/11) are expressed by many normal tissues and it has been suggested that they may represent candidate cancer diagnostic/prognostic markers. Renal cell carcinoma (RCC) is characterized by unpredictable outcome, despite the use of conventional prognostic factors. The immunohistochemical expression (IE) and the predictive value of the above kallikreins was evaluated in RCC. Included in the study were 95 patients who underwent radical nephrectomy for RCC. The median follow-up was 60 (1-180) months. Fifty seven of the 95 RCC cases were immunostained for hK5, 70/95 for hK6, 70/95 for hK10, and 69/95 for hK11, respectively. The immunohistochemical method of streptavidin-biotin-peroxidase using anti-hK5, /6/10/11 monoclonal and polyclonal antibodies was performed. The IE of all kallikreins was correlated with tumor size, histological type, histological malignancy, mitotic index, and pathological stage. The Fuhrman 4-scale grading system was used for the determination of the histological malignancy. For statistical analysis, four grades were collapsed into two and RCC cases were categorized as low and high malignant (LM and HM) respectively. Statistical analysis included Pearson Chi-square and Kruskal Wallis tests. Survival data were analyzed using Kaplan-Meier and Cox regression analysis. A Pvalue < 0.05 was considered significant. In the normal (adjacent to tumor) renal parenchyma, the epithelium of the urinary tubuli showed a cytoplasmic IE of all kallikreins. In RCC, their IE

was decreased: 33/57 cases (58%) were positive for hK5, 27/70 (39%) for hK6, 46/70 (66%) for hK10 and 32/69 (46%) for hK11, respectively. A statistically significant positive correlation was observed among the IE of all kallikreins. HM-RCC expressed all kallikreins in a higher percentage than LM-RCC, but a statistically significant difference was observed only in the case of hK6 and hK10 (55% vs. 27%,  $p=0.016$  and 79% vs. 56%,  $p=0.044$  respectively). Hk6 and hK11 showed a positive correlation with pathological stage: hK6 with both Robson and TNM 1997 staging systems ( $p=0.010$  and  $p=0.017$  respectively), and hK11 only with the Robson staging system ( $p=0.045$ ). In both the Kaplan-Meier and the univariate Cox regression analysis, hK6 IE showed a negative correlation with disease survival ( $p=0.05$  and  $p=0.038$  respectively). In univariate analysis, nuclear grade, Robson and TNM staging systems correlated with disease survival as well. However, in the multivariate analysis, TNM staging system was the only independent prognostic factor. In conclusion, although the IE of hK5/6/10/11 is down-regulated in RCC, tumors of high grade and/or advanced stage express one or more of the above kallikreins in a higher percentage. It seems that hK6 may significantly contribute to information in predicting poor disease outcome for RCC.

The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the domains, cell lines, vectors, methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Below full citations are set out for the references referred to in the specification.



Table 1

Kallikrein Polypeptide	Kallikrein Nucleic Acid Designation	GenBank Accession No.
Kallikrein 5	KLK5	AAF03101, AF135028 (mRNA join 2101..2131, 2210..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11570) (CDS join 2221..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11247), AF168768 (CDS 170..1051)
Kallikrein 6	KLK6	AFB66483, AF013988 (CDS 174..881), AF149289 (CDS 3567..3606, 4346..4502, 8211..8369, 9791..9927, 11805..11954) (mRNA join 2001..2185, 3084..3135, 3559..3606, 4346..4502, 8122..8369, 9791..9927, 11805..11957), HSU62801 (CDS 246..980)
Kallikrein 10	KLK10	AAC14266, AF055481 (CDS 614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945) (mRNA join 48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474), NM_002776 (CDS 220..1050)
Kallikrein 11	KLK11	BAA33404, AAD47815, AB012917 (CDS 26..874), AF164623 (CDS 4224..4263, 5061..5217, 5545..5810, 6627..6727..6763, 7158..7307) (mRNA join 2312..2398, 4189..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7310)

**We Claim:**

1. A method for detecting kallikrein polypeptides or polynucleotides encoding kallikrein polypeptides that are associated with renal cell carcinoma in a patient comprising:
  - 5 (a) taking a sample from a patient;
  - (b) detecting or identifying in the sample one or more kallikrein polypeptides or polynucleotides encoding the kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 ; and
  - 10 (c) comparing the detected amount with an amount detected for a standard.
2. A method for detecting kallikrein polypeptides associated with renal cell carcinoma in a patient comprising:
  - (a) obtaining a sample from a patient;
  - 15 (b) detecting in the sample one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
  - (c) comparing the detected amounts with amounts detected for a standard.
3. A method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides, wherein the kallikrein polypeptides  
20 comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
4. A method as claimed in claim 1, 2 or 3 wherein the kallikrein polypeptides are detected using antibodies that bind to the kallikrein polypeptides or parts thereof .
5. A method of detecting renal cell carcinoma in a patient, the method comprising comparing:
  - 25 (a) levels of kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
  - (b) normal levels of expression of the kallikrein polypeptides in a control sample, wherein a significant difference in levels of kallikrein polypeptides, relative to the corresponding  
30 normal levels, is indicative of renal cell carcinoma.
6. A method of any proceeding claim where the levels of kallikrein polypeptides are higher than normal levels and are indicative of advance disease and/or poor prognosis.
7. A method for monitoring the progression of renal cell carcinoma in a patient, the method comprising: (a) detecting in a sample from the patient at a first time point, kallikrein polypeptides,  
35 wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of renal cell carcinoma.

- 34 -

8. A method for determining in a patient whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels or non-metastatic levels of the kallikrein polypeptides, in a control sample wherein a significant difference between the levels of expression in the patient sample and the normal levels or non-metastatic levels is an indication that the renal cell carcinoma has metastasized.  
5
9. A method for assessing the aggressiveness or indolence of renal cell carcinoma comprising comparing: (a) levels of expression of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels of expression of the kallikrein polypeptides, in a control sample, wherein a significant difference between the levels in the patient sample and normal levels is an indication that the cancer is aggressive or indolent.  
10
10. A method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating polynucleotides from the sample, and detecting in the sample polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.  
15
11. A method as claimed in claim 10 wherein significant differences in the levels of the polynucleotides in the sample compared to a control is indicative of disease, disease stage, stage, and/or prognosis.
- 20 12. A method for determining the presence or absence of renal cell carcinoma in a subject comprising: (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides encoding kallikrein polypeptides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject.  
25
13. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the levels of nucleic acids are detected by polymerase chain reaction.
14. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the amounts of mRNA are detected using a hybridization technique, employing oligonucleotide probes that hybridize to kallikrein polypeptides.  
30
15. A method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides, and/or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides encoding same in the first sample,  
35

relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

16. A method of claim 15 wherein the first and second samples are portions of a single sample obtained from the patient.
- 5 17. A method of claim 15 wherein the first and second samples are portions of pooled samples obtained from the patient.
- 10 18. A method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides and/or polynucleotides encoding same in a first sample obtained from the patient, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient following therapy, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma in the patient.
- 15 19. A method of selecting an agent for inhibiting renal cell carcinoma in a patient the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) selecting one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.
- 20 20. A method of inhibiting renal cell carcinoma in a patient, the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) administering to the patient at least one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.
- 25 21. A method of assessing the renal cell carcinoma cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and (b) comparing expression of kallikrein polypeptides and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and wherein a significant difference in levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot maintained in the presence of the test compound,
- 30 35

- 36 -

relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses renal cell carcinoma cell carcinogenic potential.

22. An *in vivo* method for imaging renal cell carcinoma comprising:
- 5 (a) injecting a patient with agents that bind to kallikrein polypeptides, the agents carrying labels for imaging the renal cell carcinoma, and wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11;
- (b) allowing the agents to incubate *in vivo* and bind to the kallikrein polypeptides; and
- (c) detecting the presence of the labels localized to the renal cell carcinoma.
- 10 23. A method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma, the method comprising inhibiting expression of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11.
24. A method of any preceding claim comprising at least two of the kallikrein polypeptides.
- 15 25. A method of any preceding claim comprising at least three of the kallikrein polypeptides.
26. A method of claim 22 where the kallikrein polypeptides are kallikrein 6 and kallikrein 11.
27. A method of any preceding claim wherein the patient sample comprises serum obtained from the patient.
28. A kit for carrying out a method as claimed in any preceding claim.
- 20 29. A kit for assessing whether a patient is afflicted with renal cell carcinoma, the kit comprising reagents that specifically bind with kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
- 25 30. A kit for assessing the suitability of each of a plurality of agents for inhibiting renal cell carcinoma in a patient, the kit comprising: (a) the plurality of agents; and (b) reagents for detecting kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
31. A kit as claimed in claim 28 or 29 wherein the reagents are antibodies that specifically bind with protein or protein fragments corresponding to kallikrein polypeptides.
- 30

## Sequence Listing

## SEQ ID NO. 1

hk5 amino acid

5 MATARPPWMWVLCALITALLGVTEHVLANNNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGSD  
 CDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAHCRKKVFRVRLGHYSLSPVYESGQOMFQGVKSIPHPG  
 YSHPGHSNDLMLIKLNRIRPTKDVRPINVSSHCPASAGTKCLVSGWGTTSKSPQVHFPKVLQCLNISVLSQKR  
 10 CEDAYPRQIDDTMFCAGDKAGRDSQGDSSGGPVVCSLSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQET  
 IQANS

## SEQ ID NO. 2

KLK5 CDS

ggtgtctgtg cgtcctgcac ccacatcttt ctctgtcccc tccttgccct gtctggaggc  
 15 tgctagactc ctatcttctg aattctatag tgcttgggtc tcagcgagc gccgatgggtg  
 gcccgctcct gtggttccct tctacttggg gaaatcaggt gcagcgccca tggctacagc  
 aagaccccc tggtatgtgg tgctctgtgc tctgatcaca gccttgcttc tgggggtcac  
 agagcatgtt ctgccaaca atgatgtttc ctgtgaccac cctctaaca ccgtgccctc  
 tgggagcaac caggacctgg gagctggggc cggggaagac gcccggtcgg atgacagcag  
 20 cagccgcac atcaatggat ccgactgcga tatgcacacc cagccgtggc aggccgcgct  
 gttgctaagg cccaaccagc tctactgcgg gccggtgtg gtgcatccac agtggctgct  
 cagcgccgcc cactgcagga agaaagtgtt cagagtcctg ctcgccact actccctgtc  
 accagtttat gaatctgggc agcagatgtt ccaggggtgc aaatccatcc cccaccctgg  
 ctactccac cctggccact ctaacgacct catgctcatc aaactgaaca gaagaattcg  
 25 tccactaaa gatgtcagac ccatcaacgt ctctctcat tgtccctctg ctgggacaaa  
 gtgcttggtg tctggctggg ggacaacaa gagcccccac gtgacttcc ctaaggctct  
 ccagtgttg aatatcagcg tgctaagtca gaaaaggtgc gaggatgctt acccgagaca  
 gatagatgac accatgttct gcgccgtga caaagcaggt agagactcct gccaggggtga  
 ttctgggggg cctgtggtct gcaatggctc cctgcaggga ctctgtctct ggggagatta  
 30 ccttctgtcc cggcccaaca gaccgggtgt ctacacgaac ctctgcaagt tcaccaagt  
 gatccaggaa accatccagg ccaactcctg agtcatcca ggactcagca caccggcatc  
 cccactgct gcagggacag ccctgacact cctttcagac cctcattcct tccagagat  
 gttgagaatg ttcattctct cagccctga ccccatgtct cctggactca ggtctgctt  
 cccccacatt gggctgaccg tgtctctota gttgaacctt gggaacaatt tccaaaactg  
 35 tccagggcgg ggggtgcgtc tcaatctccc tggggcactt tcatcctcaa gctcagggcc  
 catcccttct ctgcagctct gacccaaatt tagtcccaga aataaactga gaagtggaaa  
 aaaaaaa

## 40 SEQ ID NO. 3

KLK5 nucleic acid

gggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt ggcttgagtc  
 tcccctgcct aaaatgcagg gagaggagg cagaaagaca ggggaagagga aggggtgggg  
 45 aagaaagaga gagagagaga gagacagaat aacacaacta cagaaacaca gagagaacac  
 acagagagcc tgggacacag ggacacacag agtcagagag aaaagagaag atagagaaaag  
 acacaaatgg agacacagag gtgtaaagaa agagagatta acagagtccc agatacacgc  
 aaaggggcag aagcacagtt ttcagggtgg tgtctatgat catcttcttt ttttttttt  
 ttttttttt tttttgagac ggagtctcgc tctgtcggcc aggctggagt gcagtggcgg  
 50 gatctcggct cactgcaagc tccgcctccc ggggttcacgc cattctcctg cctcagcctc  
 ccaagttagct gggactacag gcgccgcga ctacgccgg ctaatttttt tgtattttta  
 gtagagacgg ggtttcacgg ttttagccgg gatggcctcg atctcctgac ctogtgatcc  
 gccgcctcgg gcctcccaaa gtgctgggat tacaggcgtg agccaccgag ccgggccatg  
 atcatcttct tgactatgct gatgtgacaa gtacctaaag ccatcagact ctacccttta  
 55 aatatgcagt ttgggcccag caccgtggct catgcctgta attccagcac tttgggaggc  
 agagggtgggt gaatcacttg aggccaggag tttgagacca gcctggccaa catggtgaaa

	ctctgtcttt	actaaaaaaa	aaaaaaaaaa	aaaaaaaaatc	agccgggtgt	cgtggggcac
	acctgtaatc	ccagctatgc	tggaggctga	ggcacgagag	tcacttgaac	cctggaggcg
	gaggttgcag	tgggccgaga	tcacatcacc	gccctccagc	ctgggcgaca	gagcaagact
	ctgtctcaaa	taaataaata	aacaaacgaa	caagcagttt	gttgtacctt	agttatatct
5	aaaaaaaaaa	tgctgtcaac	aatagagca	gaagtgaat	aaaggaaaat	aaatgggcca
	agaactctaa	ggtatatttg	acaaatcatt	cagaaccttt	aaaaaagaaa	gaatcacaga
	ggcatagaaa	gacagggagg	aacagggaga	cagaaacacc	tgtggcccaa	ggagaacaaa
	acaaggctcc	taagacagac	aggaggagag	agagagagag	tgagttagag	acagacagag
	aaaaagacag	agagagagag	acagagacag	agagacagag	aggcgagagg	gatagaaaga
10	gagagagggg	tggagagaga	cacgagatat	tgagagagac	tcagaaagat	agccgagggg
	gaaccacaga	gagatggaag	aagactctga	gaaaaaacca	gagacaaaga	tggaaagagg
	agtatcgagg	gtgaacagac	agtgggtgaa	tgagcaaaat	gcagagaaga	aagcaagcaa
	tccaggcgcc	aagaatagtg	acccagagtt	ggtgagaagc	cagatcctta	aggctggggg
	aggcagggaa	ggggctggcc	tggcttccgg	agaccctcc	ccatttctccg	ggccagggag
15	gtagggagtg	acattccgga	ctgggtgggg	ggtgctctgg	gggtggagat	agggggagca
	ggaggagcta	ttgctaaggc	ccgataggca	cctcattgcc	cggaatgtg	ccccagggag
	cagtgggtgg	ttataactca	ggcccgtg	ccagagccca	ggaggaggca	gtggccaggga
	aggcacaggc	ctgagaagtc	tgcggctgag	ctgggagcaa	atccccacc	ccctacctgg
	gggacagggc	aagttagacc	tggtaggggt	ggctcagcag	gcagggaagg	agaggtgtct
20	gtgctctctg	caccacatc	tttctctgtc	ccctccttgc	cctgtctgga	ggctgctaga
	ctoctatctt	ctgaattcta	tagtgcctgg	gtctcagcgc	agtgccgatg	gtggcccgctc
	cttgtgggtc	ctctctacct	ggggaaataa	ggtaggggag	ggagggggaag	tgggttaagg
	gctccccgga	tgcctggggc	ctcccaaccc	tctgacattc	cccattccagg	tgcagcggcc
	atggctacag	caagaccccc	ctggatgtgg	gtgctctgtg	ctctgatcac	agccttgctt
25	ctgggggtca	caggtaacca	gaactctggg	gtgggagggg	tgtgggattg	ggaggactgt
	ctctgcggca	ctagagcgcc	tgtcccctgg	ggaactgtgt	gagcctgggc	atgactccgg
	gaccgggtga	atgtgagtc	ctgtctgtac	ttgtggttgt	gcgatcgtat	gtggccctgt
	gactgccacg	gtgtgtgtcg	gggaggggga	tgccttttcc	catatcaggt	gactgtgcgg
	caggtaggcac	tgaccctttg	aggctgtgtg	tgtggttttg	tgatttgtgtg	tgcatttaag
30	attgtgtgtg	gctccacagc	tgtgtgggtg	aatgcatgta	gcactggggg	tgttactgt
	gtgtttggct	gtgtgtgggt	acttggcatt	gtatatgact	gcaggatatc	gcagttcctg
	tccctgaggt	cccgggattg	cgtgcaacaa	aagtggtcac	caccatggaa	agctgtgact
	gtgtgctgct	tgcaggcgat	tatgtgattg	tggctgagtg	tgacgttatg	gatgcccgta
	tttgtgaccg	tgtgactacc	tgaagctctg	tgtaggggtg	actgtatgtg	actgtgtgtg
35	tctgtgtgag	gccgtgtaaa	tgctactgta	tgtgtgatgg	tgcagctgtg	tgtctggagt
	ttctgtctct	gcctggaggg	atagagggtg	caggggtagc	tatctctggg	agatgggtgc
	cagggtgactg	acttgcaagt	tgtgcctgtg	tgcagaagag	tatgtggcag	tctgaacatc
	tgtgcacaca	cggcacatct	gcgtggcact	gagacactgt	ggatgagggt	gtgcgatccc
	gctaggctgc	ccgggagcgt	gtgtacctgg	agacagagct	gtatgttagc	gtcactgtgtg
40	gaggcaacat	gggcgtgtct	gcagaactgc	gtgcgtgctt	ggctgttact	gctgtgtgtc
	gcgtgggtct	tggggtagtg	tcgtgaatga	tgggtgtgcc	agggccatca	gcaagggtaa
	gaaccaggcc	gggcgcgggtg	gctcacgcct	gtaatcccag	ccctttggga	ggccgaggca
	ggcggatcac	ctgaggtcgg	gagatcgagg	ccagcctgac	caacatggag	aaccccgctc
	ctactaaaaa	tacaaaaaat	tagctggtgt	ggtggcgcgt	gcctgtaatc	ccagctactc
45	gggagactgg	ggcagaaaaa	tcgcttgaac	ccgggaggtg	gaggttgccg	tgagccgaga
	tcgggccatt	gcactccagc	ctgggcaaca	agagcgaaac	tccgtctcga	aagaaaaaaa
	gaaaaaaaaa	agggtaagaa	ccagtgaatg	ggcacgggag	gactgatgat	ggagtggggc
	atgcatgtag	tctgtaggto	tgtgtgtgag	aggaggagat	tgacaggatt	gagaaggcat
	gttttcatct	gagaattcag	aaacctaggc	ctgctcttcc	cctccatgtg	gccccctaag
50	ctgagccctt	ctttcctggg	cctgctttcg	gaaccctagc	tccgcccattg	agctctgacc
	ccacctctct	tcctcaacca	cgcccttagg	ccagactcta	gtggaccccg	cctaaggcca
	cacccttttg	ggccaggctc	caccocctat	tctgtgggta	ccttctagaa	ccccctcaa
	agtcagagct	tttttttttt	tttttttggg	gacagtcttg	ctctctctcc	caggctggag
	tgcagtggcg	tgatctcggc	tcactgcaac	ctctgcctcc	caggttcaag	tgattctcgt
55	gcctccacct	cctgagtagc	tgggattaca	ggtgcgcgcc	accacgcctg	gctaattttt
	gtgtcttttag	tagagacagg	gtttcacctt	gttgccagg	ctggtctcaa	actcccaacc
	tcaggtgatc	cgccacctc	ggcctcccag	agtgcctggg	ttacaggcgt	gagccaccgc
	ccccagccca	aagtcagagc	tctttatagg	agactctaac	atgtaaccct	gaccctggcc
	ctaactaagt	caattccaaa	ccccttctcg	cctccagccc	tgacccct	cactgaggcc

	tgaccccaact	tcttgagacc	agttccatcc	ctaaagccct	ggtctccctc	ccatccccag
	gctccagccc	ccacagcttt	ggcactaccc	ctgagcttgt	ccaggaatcc	tgtaocccaat
	tttaccctca	catgtagttc	tagccaatcc	caggaatctg	tgaggtccag	tttagagtcca
	gtaaccctac	ctgagccctg	gctctgtcct	tgagcttgag	cctgggcttg	agaggtgcca
5	ctcttattct	ccaggccctg	cccctgcccc	ctcagcatgt	cagacacca	ccctctagct
	ggtctggcct	cttgagtctg	aaacccaccc	ccagcccaag	ccccgcctct	gagccccgcc
	caaccatttt	tccgttccca	gagcatgttc	tcgccaacaa	tgatgtttcc	tgtgaccacc
	cctctaacac	cgtgccctct	gggagcaacc	aggacctggg	agctggggcc	ggggaagacg
	cccggtcggg	tgacagcagc	agccgcatca	tcaatggatc	cgactgcgat	atgcacaccc
10	agccgtggca	ggccgcgctg	ttgctaaggc	ccaaccagct	ctactgcggg	gcggtgtttg
	tgcatccaca	gtggtctgctc	acggccgccc	actgcaggaa	gaagtgaagt	ggagttccaa
	gaggagggtt	ggtggggacg	gggaagtggg	ggtgggggtg	gggaagtggg	ggtgggggtg
	tcattggagg	gagggtctgt	ggggacgggg	aagtgggggt	gggggtgtca	tggaaggtga
	gggttgggtg	ggatgggttg	gggatgtggg	agcaggaggga	ggtcagattg	gggataggac
15	taaggatgga	gttttgccgg	ggagcaagg	gggaggatga	ggttgagag	gggagagtgt
	tgttgtaggg	aatgggaagg	agccaaggat	gggttggtat	tggggttagg	agcatatatt
	tgttgaatgg	tttgggatgg	aggtggaatt	gggatgtgct	ttagaattgg	gggtgggtga
	aaatcgggct	ggggtggaaa	tgaagatagc	atggagatag	ggttgagatt	gggagcagat
	atagaatgaa	ggatggggat	tggagtgttg	ggtgggggtg	gagatggttg	gatttgggct
20	tgagaatgca	tatggtgatg	gcttctgggt	agggaaagaa	ttagggttgg	gaatgggatg
	ggtttggaat	tgtgactggg	atggggacag	gcatgggatt	ggagaccaag	aggagttga
	ggatggtttg	gggaccgggg	gtggggatgg	gggtggggct	ggggctgggt	gtggggtttg
	gattggcggt	ggacgtggag	atagagatca	gggttgggtg	tgacctgccc	catcttccct
	agagttttca	gagtcogtct	cggccactac	tcctgtgcac	cagtttatga	atctgggcag
25	cagatgttcc	agggggtcaa	atccatcccc	caccctggct	actccccacc	tggccactct
	aacgacctca	tgctcatcaa	actgaacaga	agaattcgtc	ccactaaaga	tgtcagaccc
	atcaacgtct	cctctcattg	tcctctgtct	gggacaaagt	gcttggtgtc	tggtggggg
	acaaccaaga	gcccccaagg	tgagtgtcca	ggttcttctt	gataccgacc	catctctgcc
	gccttccatc	tttctccact	tctcattgtg	ttcctgtttg	acagtgcact	tcctaaaggt
30	cctccagtgc	ttgaatatca	gcgtgctaag	tcagaaaagg	tgcgaggatg	cttaccgcag
	acagatagat	gacaccatgt	tctgcgcggg	tgacaaagca	ggtagagact	cctgccaggt
	gaggacacct	ctctttattc	agcagataca	cactgagtgc	caactcggta	acatggagcg
	ttgccaat	ctgagaatcc	agcaattgcc	aagacagtca	ggaccctgt	tctcacagag
	ctcataccct	agagtagtgg	tgtttagtag	aaataatgct	gagctgttta	tgtcatttcc
35	agtttttttag	tagccacatt	aaaacaggta	aaaaaggctg	ggcgagtggt	ctcacacctg
	taatcccagc	actttgggag	gctgaggcag	gcagatcacc	tttggtcagg	agtttgagac
	tagcctggcc	aacatggcga	aactctgtct	ctaaaaaaaa	atacaaaaaa	tagcctggca
	tggtggcggg	cgctgtaat	ctcagctgct	caggaggccg	agacacaaga	atcacttaaa
	cccataccct	ggaggttgca	gtgagctgag	atcgtgccac	tcactccaac	ctgggagaca
40	gagtgacact	tttgtctcaa	aaagaaaaaa	aaaaacaagt	aaaaaagaaa	cagggtgaagt
	taactttaat	aaccatgt	atcccaaata	caatcatttc	aaagtgtaat	taatataaaa
	caattatgaa	tgagatactt	tacattcttt	tcttggtttc	atattaagtc	tttgaaagt
	agtatatatg	ttatgctgac	agcacatctc	aatttggact	agctacattt	cagggtgctca
	gtagccacat	gtggctagca	gttactgtat	tggtggcac	ggatctagag	ggaaagatca
45	gggctgtttt	gtatgggttg	gcaggtgtg	cactgcataa	agataccata	tctaataagg
	gcactccgtg	ttacagatgt	cagttttggc	agttttcagg	cgtgtggtag	ttaaagtgtct
	tgtttcaaca	aaatctgtaa	tatgacagtt	ttctagcaag	tgctggtaaa	atatcttgag
	gaaggaaaag	agaaatctgg	taggtatttt	tacaagagaa	tattttaatac	aggggattaa
	ttgcaaaagt	gctggaagg	ctggaggaac	aaagttaaaa	aataaaaaac	tctgtggtca
50	agaatctgca	taaatagggc	aatttcagag	agtggtaaa	gttaacccca	aaataaaaca
	tggttttagg	atagtaaaca	ataaggccca	atattcaaaa	aggtggtcag	gggagcctcc
	ttggagaggt	ggcatttgag	cagagaatgg	atgacacaaa	gaagctaacc	tcgtgaagtt
	taaggggaaa	gaaaaggcac	gtgcaaaggc	cctgaggcag	taaggaaatt	ggctgattca
	aagaagaaga	ggaaccaaat	gcaactggag	aacaaaagt	ggggcaacag	tagaaaagtga
55	cgctggagg	gtaggcagg	cgaatgctc	tgcaagtatt	tcttggtcac	caacacagag
	cttccctatg	ttctaattga	agctgtatct	gttgaggaag	acagaattta	aaatcaaact
	gttacatcaa	ccagaccct	tctctgtatt	caggctccca	agggatctag	aaggacgtaa
	gttaacaagc	tctcattagc	aggggtgtgt	tttcaacagt	agtttaggaag	ctggggattc
	aggagtactc	cagtccccatg	gctatgaaaa	gctcccccca	aattgtacaa	acctgacaaa



	tgcaacacct	ccccagctct	ccccatttct	tctctgtgcc	ctgggtgtgg	gggggtgggt
	tgcgaggggg	aaaactttta	acagaagaaa	gcacatctcg	gccgggctg	gtggctcaca
	cctgtaatcc	caacactttg	ggaggccgag	gcgggtggat	cactaggcca	ggagatggag
	accatcctgg	ctgacacggg	gaaacctgt	ctctactaaa	aacacaaaaa	attagccggg
5	cgtgggtggca	ggcgctgta	gtcccagcta	ctcgggaggg	tgaggcagga	gaatggcctg
	aacccgggag	gcggaacttg	cagtgaagcg	aggttgacc	actgcactcc	agcctgggca
	acacagtgg	actccgtctc	aaaaaaaaa	aaagaaaaga	aaagaaatca	catctcattc
	aagtggtggc	atttaaaact	atttagcctt	tctgtaggca	aggttagtat	cttgtttttc
	cagacctcaa	ggtgtttttt	tggttgtttt	ttcataccgg	tgtgtggtct	gggtgtggcc
10	actaaaagct	acaagcaaga	aataataaca	actacaacaa	tactaatacc	aatagtataa
	aaataatagc	atctggctaa	ttgctggaca	ctgttttaag	tggtttgcat	gcctcagctc
	attaactcat	ttacctgtta	ttattggccc	tattttacaa	acaaggagcc	aaggctcaga
	gcagtttaact	aacagcctct	caaaaagaaac	tctgcagaga	tattaaatct	aaaaaataat
	gagagaaatt	aaaccacaag	aaagttgaaa	tttagaggta	caggcagcta	agcctgtttg
15	ctttgaaaca	gtgtctgcta	ctgggaaaaa	ggcaagtctt	ggctttccta	ataattgata
	ccaggactct	gtaattcata	ttttgcatgc	atgtaagtaa	gaaatgaagc	cgggtgcaat
	ggcacatgcc	agtaatccca	gcactctggg	agactgaagt	gggaagatca	cttgagctca
	ggagttcaag	accagcctgg	gcaactaaaa	attaaaaaaa	taaaaatact	aattgttttt
	attttagtag	attttattca	taccacttac	atcattattg	tagtatgtac	atattttatt
20	cttttctttt	cttttctttt	cttttttgag	acggagtctc	gctctgtcac	ccaggctgga
	gtgcaatggc	accatatcag	ctcactgcag	catgcgcctc	ctgggttcaa	gcatttcttc
	cacctcagcc	tccaagtag	ctgggataac	aggcaccac	caccatgcct	ggctattttt
	ttttttccgt	agagatgggg	ttccaccatg	ttggccaggc	tggtcttgaa	ctcctgacct
	ccagtgtct	gcctgcctcg	gcctcccaaa	ttgctggtat	tacaggtgtg	agccaccgtg
25	cccaggtggg	agatagacat	ttctctctac	ctcaaacaga	ggtccactca	agctactttt
	cattttcttc	ataaatatta	gccgagtggc	tattttgcac	caggaaatgg	tccaggtgct
	gtggatatgg	catcaggcaa	aacagaccaa	aaacttctct	ccgcgtggac	ctcatgttcc
	ccaagtggaa	gacaggcaat	aaagagatag	ataaatatgt	agtaaattaa	aaaaaaaaaa
	aattagccgg	gtgtggtggc	ttgcacctgt	agttccagct	acttgggagg	ctgaggtggg
30	agaattgctt	gagcccaaac	gtttgaggct	gcggtaagcc	atgactgcac	tgctgcactc
	cagacagcag	cctgggtgac	aaagcaagac	gtttttgtca	gaaagaaaaa	aaaagagac
	gaaggaggga	aggagagaga	aagggaaggaa	ggaaggagaa	agaaaggaa	gaaggagaaa
	gaaagggaag	aagggaaggag	aaagaaagga	agaaagagaa	agaaagaaaa	agaaagaaag
	aaagaagaaa	gaaaagagag	aggaaggaag	gaaagaagga	aaagagggaa	aaaaatgact
35	gttgaagagc	agtgaagtatt	attataggag	ggtaattata	gggaggtatg	gggaattgaa
	gacaggaaac	acaaattagt	ccaagcgaat	ggatttctat	tgggagtgat	tctgccctta
	gaagacactg	gcaataaccag	gagacatttt	tggttgtcac	aactatatgg	aggggcatta
	ctggcaacta	atggatagat	gccaaagtgtg	ctgttcaaca	tgctatgatg	cacacggcag
	gcctccacaa	caaaccatta	tccagcttca	gatgccca	gtgccagat	cgaggaaccc
40	tcattccaggg	gctgagaacc	gtatttttgc	agaaggagg	tataaggatg	ggttggtgga
	gaatggggaa	ggaagggtgtg	tgtccagtaa	gagaaataag	gcctgcacag	gctggagggg
	agagtggag	agaaaggag	gcggagagat	acacgatgag	ggagacaggg	tggaacagaa
	agtagagacg	aagattcgag	atgtggagag	gaagggtcac	agaccccccc	gaaatgatgt
	gtggacaaca	ggaatctgga	agaggaagat	ggagtggaga	gtgacaaatg	gggtctaaag
45	gttgaacttg	gaggccaggc	atggtggctc	acgcctgtaa	tccaacact	ttggaggctg
	agggtggcga	atcacttgag	gccaggagtt	cgagaccagc	ctggccaaca	tggtgaaacc
	ccgtctctac	aaaaaaaaata	caaaaaatta	gccgggtgtg	gtgatggaca	cctgtagtca
	cagctacttg	ggaggctgag	gcaggagaat	tgcttgaacc	cgggagatgg	aggctgcagt
	gagctgaggt	caggccactg	cgctccaacc	tgggcaacag	agtaagactc	catctcaaaa
50	aaaaaaagc	tggatttgg	gtgaaatatt	aataacattc	tccctctctc	tccttttgcc
	tgtgtctcca	tctctgtctt	tttctgcatt	tcttcatctc	tgtactttcc	atctctgtgt
	gtctgttccc	atctgttctt	ccatctatgg	gcatctctgg	gtctctcatg	tctccttctg
	cccactttgc	cacatctctg	cctctctcat	gcccccttt	ctctcctgca	gggtgattct
	ggggggcctg	tggtctgcaa	tggtctcctg	cagggaactg	tgctcctggg	agattaccct
55	tgtgcccggc	ccaacagacc	gggtgtctac	acgaacctct	gcaagttcac	caagtggatc
	caggaaacca	tccaggccaa	ctcctgagtc	atcccaggac	tcagcacacc	ggcatcccca
	cctgctgcag	ggacagccct	gacactcctt	tcagaccctc	attccttccc	agagatgttg
	agaatgttca	tctctccagc	ccctgacccc	atgtctcctg	gactcagggt	ctgcttcccc
	cacattgggc	tgaccgtgtc	tctctagttg	aaccttgga	acaattttcca	aaactgtcca

gggcgggggg tgcgtctcaa tctccctggg gcactttcat cctcaagctc agggcccatc  
ccttctctgc agctctgacc caaatctagt cccagaaata aactgagaag

## 5 SEQ ID NO. 4

hk6 amino acid

MKKLMVVLSLIAAAWAEQNKLVHGGPCDKTSHPYQAALYTSGLLCGGVLIHPLWVLTAHCKKPNLQVFL  
10 GKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWG  
KTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMCLCAGDEKYGKDCQGDGSGGPLVCGDHLRGLVSWGNI  
PC GSKEKPGVYTNVCRYTNWIQKTIQAK

## SEQ ID NO. 5

## 15 KLK6 nucleic acid

CDS 147.. 881

gtcgaccac gcgtccggct ggctggctcg ctctctcctg gggacacaga ggtcggcagg  
cagcacacag agggacctac gggcagctgt tccttcccc gactcaagaa tccccggagg  
cccggaggcc tgcagcagga gcggccatga agaagctgat ggtggtgctg agtctgattg  
20 ctgcagcctg ggcagaggag cagaataagt tgggtgcatgg cggaccctgc gacaagacat  
ctcaccctta ccaagctgcc ctctacacct cgggccactt gctctgtggt ggggtcctta  
tccatccact gtgggtcctc acagctgccc actgcaaaaa accgaatctt caggctcttc  
tggggaagca taaccttcgg caaagggaga gttcccagga gcagagttct gttgtccggg  
ctgtgatcca cctgactat gatgccgcca gccatgacca ggacatcatg ctgttgccgc  
25 tggcacgccc agccaaactc tctgaactca tccagcccct tccccggag agggactgct  
cagccaacac caccagctgc cacatcctgg gctggggcaa gacagcagat ggtgatttcc  
ctgacaccat ccagtgtgca tacatccacc tgggtgtccc tgaggagtgt gacatgcct  
accctggcca gatcaccag aacatgttgt gtgtgggga tgagaagta ggaaggatt  
cctgccaggg tgattctggg ggtccgctgg tatgtggaga ccacctccga ggccttgtgt  
30 catggggtaa catcccctgt ggatcaaagg agaagccagg agtctacacc aacgtctgca  
gatacacgaa ctggatccaa aaaaccattc aggccaaagt accctgacat gtgacatcta  
cctcccgacc taccacccca ctggctggtt ccagaacgtc tctcacctag acctgcctc  
ccctcctctc ctgccagct ctgaccctga tgcttaataa acgcagcgac gtgagggtcc  
tgattctccc tggttttacc ccagctccat ccttgcata ctggggagga cgtgatgagt  
35 gaggacttgg gtctctggtc ttacccccac cactaagaga atacaggaaaatcccttcta  
ggcatctcct ctccccaacc cttccacacg tttgatttct tcctgcagaggccagccac  
gtgtctggaa tcccagctcc gctgcttact gtcgggtgtc ccttgggatgtaccttctt  
cactgcagat ttctcacctg taagatgaag ataaggatga tacagtctccataaggcagt  
ggctgttggg aagatttaag gtttcacacc tatgacatac atggaatagcacctgggcca  
40 ccatgcactc aataaagaat gaattttatt atgaaaaaaa aaaaaaaaaa aaaaaaaaaa  
agggcgggcg c

## SEQ ID NO. 6

KLK6 nucleic acid

45 mRNA join (2001..2185,3084..3135,3559..3606,4346..4502,  
8122..8369,9791..9927,11805..12483)

CDS join (3567..3606,4346..4502,8122..8369,9791..9927, 11805..11957)

50 acacttaaaa aatcttctga cttaaaaaaa aaagtatggt gattggaaaa tgtaaattgt  
catgcgtgct tggcatcaca ttctattggc caggacttcc ctggatgcta aaggctctca  
aatgccaggc tggggggctg ggacttggtc ccaagggaga tggggacca gggcacgtct  
gtgagaggag gggcaaggct agcacaggc acaggaaggt ctctctgggg caagggatac  
agagaacaga gggatcctgg tccagtggtg agaggtgcag ctctgagttg gggttgaggg  
55 tgtgggtaca gagaggaagg gacccccag agagaggagg cagagggata gggcctggct  
actgggttgt gcaacatcag acttgctgtc tgtgaagata gcacgtcctg agaagaaggt

	gctgagggtca	gtgggggacca	aatgtgagag	ggagcaccocg	gagagtatac	tgaataaccga
	agtagtccttc	atccctggag	tgatggggggg	tgacacatgc	aagatgacaa	ttagattccaa
	tgcaagacaa	agaaaaggggt	tggtctgggaa	cagtgggtca	tgccctatggg	cccagctcct
	gggaagactg	aggcggggagg	gtcgtcttgag	cccaggagggg	ttgagggtgc	cacgagcaag
5	gatcgtgcca	ctgcactcca	gcctaggcga	cagaacaaga	ccttgctctca	aaagaaaaaa
	gaactttttt	ttttaagtta	cctgtagtgc	ccagcccaag	caggtgtcga	gccagacttc
	attcctatca	ttgtccttat	tacgcagtga	cttccccctc	ctcattttctc	tccactctgc
	cacgcacaca	ccctcacctc	ccagcccata	ccaaccaccc	caaccactgc	ctgtgggttc
	ccatgtgcac	ccaggccagg	catttttcacg	gcctttcctc	ctgacctacg	cctgggtcag
10	ctttctaggc	ccaagttcaa	agacacctcc	ctaaatcttc	ccagatccct	ctgctactgc
	ccagcaccac	catcttatca	cagccccacg	tcgttcccaa	gtgctctcog	atttctgctt
	aactccatgc	ctctcgtgtg	gtgtccgcat	ctcatcaata	agtctcctca	tcctcttcca
	toctgctagc	ttcctcatcg	ctcgggaatc	atccccgcta	cttctggggg	aaactgactc
	ccttctgggc	acacacagtg	ctacccccgg	ggaaatctaa	gaagagaccc	aggagaagat
15	aagcacggag	agtcagagaa	tcaaggggaa	agaaagggag	agaggccggg	cacagtggct
	cacacctgta	atccagcact	ttgggaggcc	aaggtgggtg	gatcacctga	ggtcaggagt
	ttgagaccag	cctggccaac	atggtgaaac	ctcttcccta	ctaaaaatac	aaaaaacatt
	tagccggggc	tggtgggtggg	tgctgttaat	cccagctact	tggaagctg	aggcaggaga
	actgcttgaa	ctcaggaggc	ggaggttgca	gtgaactgag	atcacaccac	tgactccag
20	cctgagtgc	agagcaagac	tccgtcaaaa	aaaaagaaag	aaagaaagaa	aagaaggaag
	gaaagaaaaga	aggaaaggaag	gaagggagga	aggagagagag	gaagggagag	aggaaagggag
	agagagaaaa	aaagagggag	agagacacaa	atcacagagac	tgagatggga	gagagagaga
	gatggaagct	ccctcccctc	catggccagg	gagacagatg	gagcaagaga	cctcaggggt
	gggcagactt	ggaggagaag	gaccaggagg	atgtggagtg	ccgaaatctc	cagtcagggc
25	caggtgggca	gtcagagact	gcaaaggagg	actgtcagac	agggacaaaa	ggaagccatt
	gatgtaaccg	ccctcccgc	tgcccgcggg	aagagaggtt	gaggccggag	ctgctgggag
	catggcactg	gggtgctggg	aggcggacaa	agcccgatgt	ttcctggggc	ctttcccat
	cgccgctggg	cctgctcccc	agcccggggc	aggggcccggg	gccagtgtgg	tgacacacgc
	tgtagctgtc	tcocccggctg	gctggctcgc	tctctcctgg	ggacacagag	gtcggcaggc
30	agcacacaga	gggacctacg	ggcaggtgtg	tgagtacccc	caaccgcact	gaacctgggc
	aggctgcttc	ccagtgcggg	agggctctag	agcccggagt	gagggcctgc	aggtccctgg
	gtggcacaga	gagtgtctgg	ggtgcaggga	ggcctggggc	accatctgct	tgccccagag
	gccggaattt	gtcttcagac	actttctttc	tccaaaaccc	ggaggtctaa	ggactgagcc
	gactagaact	tcctctgcct	cagattcagg	ccccagcccc	tcctccctca	gaccaggag
35	tttaggtcct	agcccctcct	ccctcagacc	caggagtcca	agttcccacc	tcctccctca
	gactcaggag	tccaggcccc	cagcccctcc	tccctcagac	ccaggagtcc	aagttctcac
	ctcctccctc	agaccagga	gtccaggccc	caagcccctc	ctccctcaga	cgaagggtc
	caggccccca	gcccctcctc	cctcagactc	aggagtccag	gcccccaagc	ccctcctccc
	tcagaccag	gagtccaggc	cctcactgca	ctcagggacc	agtgtccct	tccctggagg
40	cctggtcagg	ggtcaccaag	agcagagcgt	ggggggcgga	ggaatgtgtg	tgaggagcct
	gggtaaggag	gaaaaggggtg	tagccagtct	cctgggtcag	ggacctgaga	gacaggggtt
	aaaaggacgt	tccagaagca	tctggggaca	gaaccagcct	cttccaggga	ggcctgggag
	ctgggggtgt	gtgtctggca	gtccctgcag	ccctgggctc	tgccggccct	gcgtcctccg
	cttggctctg	ccactgcatc	tgagtgtctt	ctctcctcac	ggctccccgc	atttctaact
45	ctttctgcct	cctcgtctca	aagctgttcc	ttccccgcac	tcaagaatcc	ccggaggccc
	ggaggcctgc	agcaggtgag	atcacagaca	tcacagaacc	tgccgggttg	gcgggggtgg
	tggtccattgc	gcacagagcc	aggctccgag	gaaaactccc	atacagagga	agaacgctag
	ggccccctat	ggtaaccttc	tcctgtcgac	aggaaggcaa	atcagtgcct	aagaaagtag
	aaagatctaa	tcagaatctc	accatgggtt	actggaccag	tggaactagt	tgaattctct
50	ttggcactgt	tttcgtggat	cctcttggaa	gatgtgggct	gaggaagaat	aatcaggag
	gctagatggg	aaggacagag	gtcaaggcag	gagaccatag	caggccagga	aggaaggaga
	ggatgcagag	ggagcagaca	gagggatggg	gggagggtcg	aggcagtgc	taatggacca
	tgtggcttcc	cctctcagga	gcggccatga	agaagctgat	ggtggtgctg	agtctgattg
	ctgcaggtgg	ggaaagggca	tttggatggg	ggaggcttgc	agacaggggt	gggcttgttg
55	atggagaaga	ggctggtatt	ggggatgggg	atatgcacag	ggttgggggtg	ggggagcttt
	gaaatgagga	agacgttggg	gattaggcta	aggggtgggga	atacagatag	ggagggtggt
	gggaggtggg	tttgaagata	tgagggtttg	gggtgggggtt	ggctttaggg	atggggatct
	aaacatagaa	gaggttaggag	gtagggttga	aagttggaga	gagccccgga	ataggggata
	cagttggggt	tgtaatggga	atggggtaag	tttgggagtg	gaaatacaga	gaagcttttt

5 ttttttgaga caggggtotca ctctgtcacc caggctggag tgtagtgga tgatccatag  
ttcactgcag acttgaactc ttgggtctca agtgaccctc ccacctcagc ctcccaagta  
gctgggacta caggcgtatg ccaccatacc ctgctaattt gtgtgtgtgt gtgtgtgtgt  
gtgtgtgtgt gtgtgtgtgt agatgaggtc tctactgtgtt accgaggctg gtctcaaaact  
cctgggctca agcgatcctc ctgcctcagc tgggattaca ggcataagcc actgcacctg  
accaatcttg actggagttc atgttgaggg ggatgcgctt ggtttctcca gaactcctct  
ctgactcaga tcttctctcc ctccagcctgg gcagaggagc agaataagtt ggtgcattggc  
ggacctgctg acaagacatc tcacccctac caagctgccc tctacacctc gggccacttg  
ctctgtgtgt gggtccttat ccatccactg tgggtcctca cagctgcccc ctgcaaaaaa  
10 ccgtgagttc acactgtaaa tgaacagcag atgcgactga accctgaggg tgtcttatag  
atgtcaggca ggaggtgaca taggcattccc ccccatccca gcacgaggcc atctgatagc  
caggtgcatt cggctgttgc ttaattgagt acttaattgt tgccaggccc tgcgggcata  
gcagtggaaa agaaaataaa aaaaagaaaa caaaaaaaa caagcaaaat tgcgtttttc  
ctgaacttac tttctaattg ggggaattgga tcatttgagg acctgcaggg cgtgatgggc  
15 atttggattt aattctgagc acagtaggaa gccactgggc agttttgttt ttgttgtttg  
tttgtttttt gagacacagt ctgcctctgt caccagggtt ggagtgtagt ggcattgatct  
cagctcactg caacctctgc ctcccaggtt ccagcgattc tcctgcctca gcaccccaag  
tagctgagat tacaggtgtg caccaccttg cctggctaatt ttttgtatgt ttggtagaga  
cggggtttca ccatgttggc caggctggtc tcgaactcct gacctcaggt gatccgccc  
20 cctcgccctc ccaaagagct gggattacag gcatgagcca ccaccacacc cagcctgatt  
tacattttta caagcacctt ggctaccacg tggaaactgg tctgggcaag agagagggag  
ggaggcccac gtgggggctg ttgctttcat ccggcgacat agggaggtgg cttgaaccca  
ggcggtcgca gtggggatgg agggatgttg aatatcttgg gatgtggaat tctgagactg  
agccagcaga atctggcaac gaggaacagg agggagagga agaagcacgg ctggcttccg  
25 tgtatattgtc ctgaacaact ggggtgtttt ccacgtcttt ctctgagttg tgggagaggg  
aaagagaaac aggcgggtg taggcagggg agcatctgac attttgcttt agccacgatg  
agttggagat gccggggaga tgtcccagca gggaggccag ggaggactct ggagctcaga  
ggagaggcca gggctggagg ttaaaatgaa ggcactcgtc gcaaacaggt gtattttaaag  
ccatgggact agatgagatc atccaaaaag ctggcatagt tggaggagct ggaggccca  
30 ggacaaaaac cctgggcgct gatcctcact agtcagattc acgacagctg ccacttggtt  
gatgctaact accaatcagg tgctgagtga aaccatgtac acacctttcc tggatgccc  
accacaaggg actcttggca ccatthttgca aatgaggaaa ctgaggtgca gggaaatagc  
aagtgacaat ccctggggtg gttccctga ccccaaggag accttgatg actctacca  
ccatcattca ttcctttgat gtacattgac taagagcacc tgctaagtgc cacattcgag  
35 ttgggcagtg gagattcagc aatggatggg acacacagct catccctgcc ctcgggagca  
caaggacaga aaggtgcaga caagcaaagt gagggtggg catggtggct cacgcctgta  
atcccagcac tttgggaggc cgaggtgggt ggattacctg agttcgagac cagcttggcc  
aacatggctc aacctgtct ctactgaaaa taaaaaaaat tagccaggcg tgggtggggg  
cttctgtaat tccagcaact tgggaggcta aggcaggaga attgcttga cgtgggaggc  
40 ggaggttgca gtgagccgag atcgcgccac tgcaactccag cctgaaccac agagcgagac  
tctgtctaaa aaaaaaaaaa ggaagaaaag aagcagcaaa ttgggctggc cgtggtggct  
catgcctgta atcccagcac tttgggaggc cgaggcgggt ggatcactcg agcccaggag  
tacaaagctg cagtgagctg tgatctacag aacaccactg cagatccagc ctgggtgaca  
gagcgagacc ctgtctcaaa aaaacaaaac aacaaaagaa gcaaaccctt caaaacccca  
45 tataattaca aattatgaag gaaaagaata cgggtaccta ctttagatgg aggaggttca  
ggaaggactt tctaattgaga taaaatccaa gccgaggcat gaagatggga aaaggaatgt  
tcagggcaga ggaaaggctg tgataacacc cctgaggtga gaaccgtctt gattattctc  
agaaaaataa atttcccggt cactgggggg cagaaggtgc tgggagataa ggttggaaaag  
tgactacagc cagatcacac aggggtcca gtgccaagtg gaggagccca ggttttattc  
50 ttaggacaat ggggagccat ggggtgatgtc tgagcaaggg agtgactctc tgttccagga  
atatgtatca aacacctatc ctgtgccagg tgctgatcaa cgcactggag atactatctc  
tgaatagaac aaaaaatccc atcttgacat cctagagctg cactgtctaa tatggtagcc  
atcagccaca tatagcaaat tacattgaaa ttaattgaaat ggaaaatcca caagccacat  
ttcaagtact cagcagccac ctgtagcttg tggttcccc agccacctct ggacagtga  
55 gatcgagatc atggcatcgt agcattttag ggacagcatt gctctgcaag gaggagaaat  
aacacaatga gtaaatattt aacaataaat atatagcagg tcggatgatt gtgataggtt  
ctctggtgga acagaaagca ggggagggag ataggaattg cctactaaca ggtatttgta  
ttttaattgg gcaactaagg aaggcttccc tgagaggcga catttaaagg aagtgaggga  
gtgagctatg cagataactg gaggacagac ttgctggcag agggaacagc agtgcaaaag

	ccctgaggtg	ggaagatcac	tattgtgttc	aaggcaagac	agggagccca	gcgtttggct
	ggagcagagg	gagagaaggg	gagagtggga	ggagaagatg	tctgtgagat	gatggggcag
	tgcttgcaag	gcctggtgtg	ccacgttgag	aactttggct	ttgattctga	gtgagatggg
	agtcatagga	ggggctgagc	agaggaggca	caggaccaac	ttacattggt	aaaatatctc
5	tggttgcttt	gtggaggatg	gactgtgggg	gaccagagac	agagcagggg	gcccagttag
	gaggctactg	ctctagtcca	ggtaggaagt	gaaaaggcag	ctcaaaccac	gatggtagcc
	gtgggaaagg	tgagatgtgg	ccagattctg	gatatgcttc	agagaggcaa	aaggaattct
	ggacagcttg	gatgtagggc	atgaaataaa	gagagtgaag	aatagccccc	aagattattc
	tgaaggatg	gaattgccat	ttaccagct	ggggaagact	gtgggaggag	caggccagcg
10	attcatgact	tcccagccct	ctctgaagcc	tcaactgcag	cccaagggct	ccaggtgaga
	cccagccctc	ttccttccca	ggaatcttca	ggtcttcctg	gggaagcata	accttcggca
	aaggagagtg	tcccaggagc	agagttctgt	tgtccgggct	gtgatccacc	ctgactatga
	tgccgccaag	catgaccagg	acatcatgct	gttgccgctg	gcacgcccag	ccaaactctc
	tgaactcatc	cagcccttcc	ccctggagag	ggactgctca	gccaacacca	ccagctgcca
15	catcctgggc	tggggcaaga	cagcagatgg	tcagtagtgg	gaggctggtg	gggagcaggc
	tactggctac	ttggggaagt	gtgccaaagg	atggggagtg	ggaaaattgg	tgaggggcca
	tgggaagatg	ggctaattgt	gaggaccaat	gggacagggt	ttcaatggga	gaaaggtcaa
	gggggagggg	gagtgaattt	gggagctggg	ccagtgaagt	aacagccaat	ggaaaatgta
	gaccaatggg	tgaatagcat	gggagagatg	gaacataaga	tgaaggttca	ataaagaggg
20	aaggtcagtg	gggagatgct	aatcagggaag	gatgtcaaag	gtcaaagggg	actgatcagg
	attcattgaa	cagcaggaag	gaataatgga	gaaggaactg	atggaagaag	agaaaccaat
	aaagcacaaa	agccaactga	aggatgtgaa	ttgagacagt	gaatgggggt	atagctgatg
	gaagagggag	taaggggaaa	ggatcaatgg	tccagaggag	tcactagagg	aaaaaacagg
	tccaatagat	cagcaggatc	catgaagggt	ggcctgtgtg	tgaaggggca	ataagaaagg
25	tgaaccattg	gatgaagggc	cagtgggaag	gcagagacaa	tggggggagg	tgcggcaagt
	tagaaaagga	ccaatgaggg	aggtggacca	ttgatgaag	ggctaatagg	aaggggagagc
	cagtggggga	tggtagggcc	agttagaaaa	ggaccaagga	gggaagcaga	ccaataggaa
	gagagagcca	atgaggggag	gcagggccag	ttaggaaagg	accaatgagg	aaggtagacc
	attggaggaa	ggccaatag	aaagggaagg	tccatgaggg	aggggtggga	cagttagaaa
30	aggaccaatg	atggagggtg	accattggat	gaagaaccaa	tagaaaggaa	gaaccaatgg
	gagagggcat	ggccagttag	gaaaagacca	atggtcacag	agtgaccaat	caagatgaat
	caatgggcag	gaagtgtcca	atgaagaatg	gactactgat	caggaggggt	acagtagagg
	agggcgtaac	agaggaagag	tcctccaggt	caactgaaac	tactgaagaa	ggtgggacca
	gtggaagaga	gaaaagtggg	ggagggacct	aagagaaaag	gaaaaccaat	aggaatgag
35	gactcctgga	gaagagacta	ttaatgagga	agacagccaa	tgggggggaa	gaatgataga
	aagagggacc	aattaggagg	cagggacgat	ggtaatgaga	tgtaaagatg	agagacaaac
	aggaagaggg	gtgccaatag	aaaagaggga	ccaatagagg	atggaggact	tataggggtt
	gggggggtgac	tggggaggat	gaggggagtg	caaggcctgg	gctgagtctg	gcccattctc
	cccctaacag	gtgatttccc	tgacaccatc	cagtgtgcat	acatccacct	ggtgtcccgt
40	gaggagtgtg	agcatgccta	ccctggccag	atcacccaga	acatgttgtg	tgctggggat
	gagaagtacg	ggaaggattc	ctgccagggtg	aggtgacccg	gatctgccac	ttacacagcc
	agggacagga	cgaagtccac	aaaacatggc	cagacacagg	aagagagaga	cacaggccaa
	aagagagctt	tacagagaca	gatagagaca	ggctgaggga	gaaccaagc	cttgaanaag
	agagacttag	ttcaacacac	agagacacag	tcagggatat	gcagagatat	aaagacacag
45	ccagcagaga	caggaagtgc	agagacaagg	atggaggccg	cgggatcaag	aaccagagag
	gccaggagca	gcggctcatg	cctgtaatcc	cggcactttg	ggaggccgaa	gcaggaggat
	cacctagggg	caggagttcg	agaccagcct	gatcaacatg	gtgaaaccct	atctctacta
	aaaatacaaa	aattaggatg	ggcacagtgg	ctcatgcctg	taatcccagc	accttgggag
	gccgaagcag	gaggtacacc	tggggtcagg	agttcgagac	cagcctgac	aacatgggtg
50	aacctatct	ctactaaaaa	tacaaaaatt	aggatgggca	cagtggctca	tgctctgaat
	cccagcacct	tgggaggccg	aagcaggagg	atcacctggg	gtcaagagat	tgagaccagc
	ctggccgata	tggtgaaacc	ctatctctac	taaaaataca	aaaattagct	gggcctgggtg
	caggcgcttg	tagtcccagc	tactcaggag	gctgtggcag	gagaatcact	tgaacctgga
	ggcggagggt	gttgagatga	gtcgagatca	tgctactgca	ctccagcctg	gcaacagagc
55	aagattccgt	ctcaaaaaaa	aacaaaaatt	caaaaaattac	gcaagcatgg	tgggacacac
	ctgtagtccc	agctactcgg	gaggctgagg	ctggagaatt	gcttaaaccc	aggaggcaga
	ggctgagtg	agctgagatc	acgccactgc	actccagcct	ggggacagag	ccagactctg
	tctaaaaaca	aaaagaacca	aagagaagta	gtaaggaagc	agatggtgtg	aggggactgt

```

ccttcctcaa acagagcccc cacgagtcct gctcagaaac gaccaggctc tggaggaggg
agacactagc tggggaaagg ggactccctc ccgaataactt taacttgggt ttctccatt
gtcatccatc caggctctcc tctttatgcc agaataacta atgcactgag ggatgtgcag
agaccaacca agggggagac acaggcagaa acggagacac aggcagaaac agggacagag
5 acagggaag cgatacatag caagttggac gcaaagaaag ggcaggtggg cgagactgtc
ctcaagacac gaggtggaga ggtgtccctg gacagaatag tgccaggcat atctctccct
gggccctccc tacctctccc acctgggtct tctcgtctcc tctccccct cctccctctc
ctcctcttcc tctcctcct cctccctcat catcttcttc tttctctct tctccatcg
gtctctacac ctctgcctct ctccacacct ctcagtctcc attcttaaat tgtttctctt
10 tcttgctctc tatgttcttc tgcatcttgg cattcctatc tctgtgtctt tgagtctctt
ttattctctc tctaccattc tctctctgtg cctttgtgtg tcttactgtc tctctctctg
tctctctgtc cctgagtcct tctctccatc tttcagtaag tacctctgtc cctttctacc
tctctctctg tcacacacac acacacacac acacacacac acacacagtc
tctgggtttc tatctgtatc tgactttctc cctctttcct gcagggtgat tctgggggtc
15 cgctggtatg tggagaccac ctccgaggcc ttgtgtcatg gggtaacatc cctgtggat
caaaggagaa gccaggagtc tacaccaacg tctgcagata cacgaactgg atccaaaaa
ccattcaggc caagtgaccc tgacatgtga catctacctc ccgacctacc accccactgg
ctggttccag aacgtctctc acctagacct tgccctccct cctctcctgc ccagctctga
cctgatgct taataaacgc agcgacgtga ggtcctgat tctccctggg tttaccocag
20 ctccatcctt gcatcactgg ggaggacgtg atgagtgagg acttgggtcc tgggtcttac
ccccaccact aagagaatac aggaaaatcc cttctaggca tctcctctcc ccaaccttc
cacacgtttg atttcttctc gcagaggccc agccacgtgt ctggaatccc agctccgctg
cttactgtcg gtgtccccctt gggatgtacc tttcttctac gcagatttct cacctgtaag
atgaagataa ggatgataca gtctccataa ggcagtggct gttggaaga ttaaggttt
25 cacacctatg acatacatgg aatagcacct gggccaccat gcactcaata aagaatgaat
ttt

```

## 30 SEQ ID NO. 7

KLK6 nucleic acid

CDS 246..980

```

35 agggcgacaa agcccgattg ttctctgggc ctttcccat cgcgctggg cctgtctccc
agcccggggc agggcgggg gccagtgtgg tgacacacgc tgtagctgtc tccccggctg
gtggctcgc tctctctgg ggacacagag gtccgaggg agcacacaga gggacctacg
ggcagctgtt ccttccccgc actcaagaat ccccgagggc cgggaggcct gcagcaggag
cggccatgaa gaagctgatg gtgggtctga gtctgattgc tgcagcctgg gcagaggagc
40 agaataagtt ggtgcatggc ggacctgctg acaagacatc tcaccttac caagctgccc
tctacacctc gggccacttg ctctgtgggt ggtccttat ccactccactg tgggtctca
cagctgccc ctcgcaaaaaa ccgaatcttc aggtcttctc ggggaagcat aacctcggc
aaaggagag ttcccaggag cagagtctct ttgtccgggc tgtgatccac cctgactatg
atgccgpcag ccatgaccag gacatcatgc tgttgcgcct ggcacgccc gccaaactct
45 ctgaactcat ccagcccctt cccctggaga gggactgtc agccaacacc accagctgcc
acatcctggg ctggggcaag acagcagatg gtgatttccc tgacaccatc cagtgtgcat
acatccacct ggtgtccgt gaggagtgtg agcatgccta cctggccag atcaccaga
acatgttgtg tctggggat gagaagtag ggaaggattc ctgccagggt gattctgggg
gtccgctggt atgtggagac cacctccgag gccttgtgtc atggggtaac atccctgtg
50 gatcaaagga gaagccagga gtctacacca acgtctgcag atacacgaac tggatocaaa
aaaccattca ggccaagtga ccctgacatg tgacatctac ctcccgacct accacccac
tggtctggtc cagaacgtct ctacactaga ccttgccctc cctcctctcc tgcccagctc
tgacctgat gcttaataaa cgcagcagc tgagggtcct gattctccct ggttttacc
cagctccatc cttgcatcac tggggaggac gtgatgagtg aggacttggg tctcgtgtct
55 tccccacc actaagagaa tacaggaaaa tcccttctag gcatctctc tccccaccc
ttccacacgt ttgatttctt cctgcagagg ccagccacg tgtctggaat cccagctccg
ctgcttactg tcggtgtccc cttgggatgt acctttctc actgcagatt tctccactgt

```

aagatgaaga taaggatgat acagtctcca tcaggcagtg gctgttgga agatttaaga  
tttcacacct atgacatata tgggatagca cctgggccgc catgcactca ataaagaatg  
tatttt

5

## SEQ ID NO. 8

Hk10 amino acid

MRAPHLHLAASGARALAKLLPLMAQLWAAEAALLPQNDTRL D

10

PEAYGAPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGGDDHLL  
LLQGEQLRRTTRSVVHPKYHQSGPILPRRTDEHDLMLLLKLARFVVPGRVRALQLPY  
RCAQPGDQCQVAGWGTTAARRVKYNKGLTSSITILSPKECEVFYPGVVTNNMICAGL  
DRGQDPCQSDSGGPLVCDLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN

15

## SEQ ID NO. 9

KLK10 nucleic acid

Gene 1...1580

CDS 220...1050

20

catcctgccacc cccctagcct tgctggggac gtgaaccctc tccccgcgcc tgggaagcct  
tcttggcacc gggaccggga gaatccccac ggaagccagt tccaaaaggg atgaaaaggg  
ggcgtttcgg gcactgggag aagcctgtat tccagggcc ccccagagc aggaatctgg  
25 gaccaggag tgccagcctc acccagcag atcctggcca tgagagctcc gcacctccac  
ctctccgcgc cctctggcgc ccgggctctg gcgaagctgc tgccgctgct gatggcgcaa  
ctctggggccg cagaggcggc gctgctcccc caaaacgaca cgcgcttgga cccgaagcc  
tatggctccc cgtgcgcgcg cggtctgcag ccctggcagg tctcgtctct caacggcctc  
tcgttccact gcgcgggtgt cctgtggag cagagttggg tgctgacggc cgcgcactgc  
30 ggaaacaagc cactgtgggc tcgagtaggg gatgaccacc tgctgcttct tcagggagag  
cagctccgcc ggaccactcg ctctgttgtc catcccaagt accaccaggg ctcaggcccc  
atcctgccaa gccgaacgga tgagcacgat ctcatgttg tgaagctggc caggccccta  
gtgctggggc ccgcggtccg ggccctgcag ctccctacc gctgtgtcga gcccgagac  
cagtgcagg ttgctggctg gggcaccacg gccggccgga gagggaagta caacaagggc  
35 ctgactgct ccagcatcac tatcctgagc cctaaagagt gtgaggtctt ctaccctggc  
gtggtcacc acaacatgat atgtgctgga ctggaccggg gccaggacc ttgccagagt  
gactctggag gcccctggt ctgtgacgag accctccaag gcacctctc gtggggtgtt  
taccctgtg gctctgccca gcacccagct gtctacacc agatctgcaa atacatgtcc  
tggatcaata aagtcatacg ctccaactga tccagatgct acgctccagc tgatccagat  
40 gttatgctcc tgctgatcca gatgcccaga ggctccatcg tccatcctct tccctccag  
tcggctgaac tctcccttg tctgactgt tcaaacctct gccgcccctc acacctctaa  
acatctcccc tctcactca tccccacc tatccccatt ctctgcctgt actgaagctg  
aatgcagga agtggtggca aaggtttatt ccagagaagc cagggaagcc gtcacaccc  
agcctctgag agcagttact ggggtcacc aacctgact cctctgccac tccctgctgt  
45 gtgactttgg gcaagccaag tgccctctct gaacctcagt ttctcctat gcaaatggg  
aacaatgac tgccctacct ttagacatgt tgtgaggaga ctatgatata acatgtgtat  
gtaaatcttc atggtgattg tcatgtaagg cttaacacag tgggtggtga gttctgacta  
aaggttacct gttgtcgtga

50

## SEQ ID NO. 10

KLK10 nucleic acid

Gene 1..5574

mRNA join(48..120,605..701,2455..2635,3589..3863,4195..4328, 4793..5474)

55

CDS join(614..701,2455..2635,3589..3863,4195..4328,4793..4945)

Promoter 1...47  
 5'UTR join(48..120,605..613)  
 exon 48...120  
 exon 605...701

```

5      ttgggggtcaa aaggggaaggt cccgccaggg gtccctgggc agaggatacc agcggcagac
      cacaggcagg gcagaggcac gtctgggtcc cctccctcct tcctatcggc gactcccagg
      tgaagctacc tgcaccccac ccgggttggg gtggattgcg agaggatggg tgggaacccc
      cgggccacag gcaggagccg gcttagagcc tcggtttctc cactgcggga cgcggaagtc
10     cccccgtgt gaggttgaga aagaggctcc cactggctcc gagcctcgga tccccacccc
      ggcgctgaag gagggggaac cctcgggcgc gccgtggctg cagccagggt agctggggcg
      cggagagcgc tccactcggg cacagggagg acgggaagat gccgcgaggg gcgtcattag
      ggtaattgtg cccattaccg tgttccagcc cgaatctccc gtctgccagc ccctgggggtt
      atcgggtgca ggtcaaaagg gtgcttgccg gctgggggtg ccaggctgg gcgcatgagc
15     gcggcgagggt gggggtctct aacggagcat ctgttttaac ccgccctgc acacacccca
      gcagatcctg gccatgagag ctccgcacct ccacctctcc gccgcctctg gcgcccgggc
      tctggcgaag ctgctgccgc tgctgatggc gcaactctgg ggtaagggtg gggacagggg
      gcggggagag gcgccgggtg gaggcacggg cgggagggca atgtgttccc gtcaccaagc
      ccgcgcgacc tctcctcccc cgagacccca gcacccaccc agcgctccgg agcacggccc
20     gcccccaagt cagctgggcc ctctctctgg ctccggccct gggtgaccog ccccaactcag
      gccctgtccg attcttgcca ccgggacctc cgctcttccg tggactcttc ggctgtttct
      ttctcctcct cttacgcgcg cccatcccg ccgcgtcca ttttactacta ccgtgttttg
      ttttgtttgt ttgtttgttt gagacggagt ctgcctctgt cgcccaggct ggagtgcagt
      ggcgcgatct cggctcactg caagctccgc ctcccggtt cacaccattc tctgtcctca
25     gcctcccgag tagctgggac tacaggcgcc cgccaccaag ccgggctagt tttttgtatt
      ttttagtagag atgggatttc accgtggtct cgatctcctg gcctcgtgat ccgctgcct
      cggcctccca aagtgcctgg attacaagcg tgagccaccg ctcccgccca caccacagtg
      ttttatcctg agtcttgccct taccgctttt tgccctctcc cctcactttt tttcttctc
      ttcccttttc tctctctttt ttctttttct ttctttcttt tctttctttc gttcttctt
30     tccttcttcc ctttcccttc ttcccttctg ttgtttcttc tttcttgttt tactttctct
      cttatttttt cttctttctt tcttgttttt ttctttcttc tctctttttc tttcttctt
      tttttttttt tttttttgag acagggcagt gctctgtctc cgtggctgga gtacagtggc
      ccaatcagag ctcaactgcag cctcgacctc ctgggctcaa gcgatactca gcctccagag
      tagctggttac cacaggcatg caccaccaca tccggctttt tttttttttt ttttttttt
35     tttttttgag acagggtctc actctgtcgc ccagactgga gtgcagtggc ccaatctcgg
      ctcatgcaa cctccacctc ctgggctcaa gcgatactcc cacctcagcc tcccaggtag
      ctgtgactac aggcgcgatg ctccgcgact acttttttgt tgttgttgtt gtttgttgt
      tttttagag actgggtctt gctgtgttgc ccgggctggg cttgaattcc cgagctcaag
      cggccaacc gcctcggctt cccaaagtgc tgggattaca ggcgtaaacc actgcgcccc
40     acccctctcc tggttttcaa tcccgttttg ttattcacac cccttctct ccccgatccc
      cgagttctat ccccgacccc ttacctcccc gccgcgttca atccccgccc ctctatcgac
      cagcgacgtt ctagccagct ctccaggcgc gctgcgttca gtccctgccc tccagaccca
      ccctattctg tctcattact ccacgctacc ctatcccagc ttcttccac tttcagcgcc
      ttcttctcct cccattcctt cgggtgcacgc gaaaccccca atatttccct accaccctcg
45     cgttctgggt gcgtcccccg tccccgaacg cagtccagtg ccacagccca gctccaacc
      caaaccocaga cctgcctc cgtgctttga ttccgtcccc tttctttctc ccagccgcag
      aggcgcgct gctccccc aaacacacgc gcttggaacc cgaagcctat ggcgccccgt
      gcgcgcgcgg ctgcagccc tggcaggctc cgctcttcaa cggcctctcg ttccactgcg
      cgggtgtcct ggtggaccag agttgggtgc tgacggccgc gcaactcgga aacaagtagg
50     aggagatcca tccccgagga cgccacgggg ggctgtggag gcggcctoca gggaggagcg
      ggcaggcggg ggtctctcgg aactcccaca gctggagggt cgggtccccg tgtccttcca
      gcaggaggag agaccgggct tgcgctgtgg ccgccagggg acggtgtggt ccttttccgc
      atttctgggc ccgtcactcc tctcccgtg attctccttg agctctagga ggaggtgggt
      gcctgcaacg gatagaagcc agggctccgt gtggtcagga atttagaact aaagggaaaag
55     gttcacttcg tgagtccccg ttgaaggagg aagggttggg tattaccaca gagaaaatgt
      ggagttgggc tgggctcggg ggctcacgcc tgtaatccca gcactttggg agggccaagg
      ggggtgatca cctgaggtca ggagttcaag accagcctgg ccaacatggt gaaaccactt
      ctcaactaaa aataaaaataa aataaaaaat aaaaaatttt aaaaaaatta aaaaaaaa
      aaggctgggt gtggtggcgg gtgcctgtaa tcccagctac tcaggaagga ggtcagggca

```



5 ggagaactgc ttgaacctgg gaggtggagg ttgcagtgag ccgagattgc gccattgcat  
tctagcctgg gtgacaagag cgaaactctg tttcaacaaa gaaaagaaaa agagaaaaaga  
aaatgtggaa ggcttaccta ggtgtccagg cccccagccc tctcaattc ctgcagatcc  
tcagagctca aacaactgat tctctctccc catgtccact gaggtccctt tctcccacaa  
5 ggccctcttc cctcagactc ttcctatctc caggccctgc ttcactgccc acctgctttc  
ccagtccttg tgaagggttt gccttcacat gcctcttctt tccccaggc cactgtgggc  
tcgagtaggg gatgaccacc tgctgtctct tcagggcgag cagctccgc ggacgactcg  
ctctgttgat catccaagt accaccaggg ctccaggccc atcctgcaa ggcgaaacgga  
tgagcacgat ctcatgttg taaagctggc caggcccgtg gtgcccgggc cccgcgtccg  
10 ggccctgcag cttccctacc gctgtgctca gcccgagag cagtgccagg ttgctggctg  
gggcaccacg gccgcccga gaggaagag ctggggctct gaggccagaa cctcaggagg  
agggggctga gggcctgaac ccctgggtct gaggaaggat gggctgggga ctggattcct  
ggatctgagg gaggacgggc tggggctcta gatgcctggg tctgtgagtc tgaggggagg  
aggggctggg ggctggact cctgggtcta agtggggagg ggctggggcc aggatcttg  
15 agtctgaagg aggaggggct ggggcttagg atagaaacgg tcttgatct ggactcctgg  
ctccccaagg attgggggct ggaccaggg attactggca tattctccct tcagtgaagt  
acaacaaggg cctgacctgc tccagcatca ctatcctgag ccctaaagag tgtgaggtct  
tctacctgg cgtggtcacc aacaacatga tatgtgctgg actggaccgg gggcaggacc  
cttgccaggg aggtctgaa caggagaggt ctctgactcc tgggaggagg gacaggagg  
20 ttatgggaaa agagcagacc ctgtgcccga tcccaaactc cattcccaaa cccatccttg  
accccaactc ttaccagac ctaacccct cctcatccct atcctcaatc ccatttccat  
cctaacccca cccattccc atctccaagc ccattttcat cccctcacct tccatgaact  
acaatcccaa cccaagtctc actgtgcctt cattctcatc cccagccca acctcccata  
acctgaagtc cacctccatt cctaccttcc agctcatacc taattccaac cccatcccat  
25 cctcgtcttt atcccaaccc aaccccttcc ttcccacca ctgcccaga tcccaaagt  
acagctctca cgttggcaca tttatttgat ctctcctttc tgccaccccc agagtgactc  
tgaggggccc ctggtctgtg acgagaccct ccaaggcatc ctctcgtggg gtgtttacc  
ctgtggctct gccagcatc cagctgtcta caccagatc tgcaaatata tgcctggat  
caataaagtc atacgtcca actgatccag atgtacgct ccagctgac catagtgtat  
30 gctcctgctg atccagatgc ccagaggctc catcgtccat cctcttctc cccagtcggc  
tgaactctcc cctgtgtgc actgttcaaa cctctgccgc cctccacacc tctaaacatc  
tcccctctca cctcattccc ccacctatcc ccattctctg cctgtactga agctgaaatg  
caggaagtgg tggcaaagg tttattccaga gaagccagga agccggtcat caccagcct  
ctgagagcag ttactgggt caccacaact gacttctct gccactcccc gctgtgtgac  
35 tttgggcaag ccaagtgcct tctctgaacc tcagtttcct catctgcaaa atgggaacaa  
tgacgtgcct acctcttaga catgttgtga ggagactatg atataacatg tgtatgtaaa  
tcttcatgtg attgtcatgt aaggctaac acagtgggtg gtgagttctg actaaaggtt  
acctgtgtgc gtgatctgac cacgtcccg tgaaagcgtg tgtccaggga agaagtgcac  
agggtagccc ccaatcccaa ccttccatcc ccaaccctta gggatgatgg aaga

## SEQ ID NO. 11

Hk11 amino acid

45 MQRRLRLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA  
TGLVGGETRIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIV  
HLGQHNLLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVITWAVRP  
LTLSSRCVTAGTSCGISGWGSTSSPQLRLPHTLRANITIIHQKCNAYPGNITDTM  
VCASVQEGGKDSQGDSSGGLVCNQSLQGIISWGQDPCAITRKPGVYTKVKYVDWIQ ETMKN

50

## SEQ ID NO. 12

Hk11 amino acid

MRILQLILLALATGLVGGETRIKGFECKPHSQPWQAALFEKTR  
55 LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLLQKEEGCEQTRTATESFPHPGFNNSL  
PNKDHRNDIMLVKMASPVITWAVRPLTLSSRCVTAGTSCGISGWGSTSSPQLRLPHT

LRCANITIIIEHQKCNAYPGNITDTMVCASVQEGGKDSQGDSSGGPLVCNQSLQGIIS  
WGQDPCAITRKPGVYTKVCKYVDWIQETMKN

5 SEQ ID NO. 13

KLK11 nucleic acid

```

aggaatctgc gctcgggttc cgcagatgca gaggttgagg tggctgcggg actggaagtc 61
atcgggcaga ggtctcacag cagccaagga acctggggcc cgctcctccc ccctccaggc 121
catgaggatt ctgcagttaa tcttgcttgc tctggcaaca gggctttagt ggggagagac 181
10 caggatcatc aaggggttcg agtgcaagcc tctctcccag ccctggcagg cagccctgtt 241
cgagaagacg cggctactct gtggggcgac gctcatcgcc ccagatggc tcttgacagc 301
agccactgc ctcaagcccc gctacatagt tcacctgggg cagcacaacc tccagaagga 361
ggagggctgt gagcagaccc ggacagccac tgagtccttc cccaccccg gcttcaacaa 421
cagcctcccc aacaaagacc accgcaatga catcatgctg gtgaagatgg catcgccagt 481
15 ctccatcacc tgggtgtgtc gacccctcac cctctcctca cgctgtgtca ctgctggcac 541
cagctgcctc atttccgggt ggggcagcac gtccagcccc cagttacgcc tgcctcacac 601
cttgcgatgc gccaacatca ccatcattga gcaccagaag tgtgagaacg cctaccccg 661
caacatcaca gacccatgg tgtgtgccag cgtgcaggaa gggggcaagg actcctgcc 721
gggtgactcc gggggccctc tgggtctgta ccagtctctt caaggcatta tctcctgggg 781
20 ccaggatccg tgtgcgatca cccgaaagcc tgggtgtctac acgaaagtct gcaaatatgt 841
ggactggatc caggagacga tgaagaacaa ttgacttga cccaccacc acagcccatc 901
accctccatt tccacttggg gtttgggtcc tgttcaactc gtttaataaga aaccctaagc 961
caagaccctc tgcgaacatt ctttgggcct cctggactac aggagatgct gtcacttaat 1021
aatcaacctg ggttgcgaaa tcagttagac ctggattcaa attctgcctt gaaatattgt 1081
25 gactctggga atgacaacac ctggtttgtt ctctgttgta tcccagccc caaagacagc 1141
tcttgcccat atatcaaggt ttcaataaat atttgctaaa tgagtg

```

SEQ ID NO. 14

KLK11 nucleic acid

30

gene 2313..7622

mRNA join(2313..2398,4189..4263,5061..5217,5545..5810,  
6627..6763,7158..7622)

35

CDS join(4224..4263,5061..5217,5545..5810,6627..6763, 7158..7310)

```

tgataatagt gttctctctc ctcatgtgtc agggccccag ccattgtcct tgagagaatg 61
40 ctogactctt tatgttgtct tgacagcctc ccctgagatt ggtcattaat gactgtgctc 121
tctctcctca ttggtcaggg cccagcccat tgccttgag agaacctctg tcttttatgg 181
agttccaccc ttcttccctg ggattggccc ctgagagacag tggttcttct cttttggtta 241
gccattgcc a ttgtcctccg ggaaagtgat tatactcttt tgtctaataa ccagacttgg 301
agccctcccc aaggcccagg actgggttga agggttgggg aggaaaaacag aaataagatg 361
45 tctcccttgt tcagacagta cttctcttcc cttccagggt gattctgggg gccccctggg 421
gtgtggggga gtccttcaag gtctgtgtgc ctgggggtct gtggggccct gtggacaaga 481
tggcatccct ggagtctaca cctatatatt caagtatgtg gactggatcc ggatgatcat 541
gaggaacaac tgacctgttt cctccacctc caccocacc ccttaacttg ggtacccctc 601
tggccctcag agcaccaata tctcctccat cacttcccct agctccactc ttgttggcct 661
50 gggaaacttct tggaaacttta actcctgcc a gcccttctaa gaccacagag cggggtgaga 721
gaagtgtgca atagtctgga ataaatataa atgaaggagg ggccatgtct gtccatttga 781
agtcctcatg ctggttgaga ctggaagaag gactcagcag tttccctatc tcataggagt 841
agaaacagag ctcaataaag gccaggcaca gtggctcaca cctgtaatcc catcactttg 901
ggagactgag gcagggtgat cacctgaggt caggaaactc ggaccagcct ggtcaacata 961
55 gtgaaacccc aactctacta aaaatgcaaa aattagccag gcatggtggc gcatgcctgt 1021
aatcccagct actcaggagg ctgagacagg agaataagcat gaaccctga ggcagaggct 1081
gcagcgagcc gagattgaac cattacactc cagcctgggc gacagagcga gactccatct 1141

```

	caaaaacaaa	caaacaaaaa	accagtgct	caaataaggat	gagggctctc	cctgagtagt	1201
	tactcagaaa	tggagtagaa	aaagttactt	ttaataatat	aggccgggtg	cagtggccca	1261
	cgctgtaat	cccagcactt	tgggaggccg	aggtgggagg	atggccttgag	ctcagatttc	1321
	gagatcagcc	tggcaacaca	gtgaaatctt	gtcactacaa	aaacacaaaa	aattagctgg	1381
5	gtgtggtggt	gcgtgcctgt	agtcccagct	acttgggaag	ctgaggtggg	aggatcaccc	1441
	gagccgggga	ggtggaggct	gcaaagagcc	gagatcatgc	cactgcactc	cagcctgggc	1501
	aataaagtga	gaccttgtct	caaaaaacaaa	aaccagcaa	tataaataag	acacatgttt	1561
	cttcatctgg	cataatagaa	atagtgccca	gagcttataa	gcttttcaag	agtccacaaa	1621
	agacccgaaa	aagaaaaaga	aaattgttag	ctccaaaata	ccagatgaaa	gctgcaaagt	1681
10	caacatttat	gaccatttaa	tccaatgtcc	ataaaacgta	gcattcttcc	cactagccaa	1741
	ctgcagttta	ctttcttgta	atgaagcata	cattgtatct	ttaatgtggg	acgtggcttt	1801
	gttctaataa	gacgaagggg	ggagtgcagg	cttggaagac	aggagagctc	agcctacgtc	1861
	tttaatcctc	ctgcccaccc	cttggttctc	gtctccactg	ggactcaaga	ggtgaggaga	1921
	gaccatctcc	ccaaatgcac	tgaagggaag	ctggaggagg	gagggagtga	gggggtgatca	1981
15	taccagcgga	ggcacatttg	ctgagccccc	ccgcagctcg	ctctttccaa	gtggaccctc	2041
	ctggaagcct	gatcccaacc	tcccctgcaa	gcaggtctgt	cacccccatc	tctcagatga	2101
	agaaactgag	ccttgcaggg	gtggagtccc	ttgtccccac	gtcataaggg	tagtcatagt	2161
	agtaggaaga	ggaagcacct	aggtttgagg	ccagggtctg	ctgctgtcag	aacctaggcc	2221
	ctcccctgcc	ttgtctccaca	cctggtcagg	ggagagaggg	gaggaagacc	aagggaaggg	2281
20	acctaactga	aaacaaacaa	gctgggagaa	cgaggaatct	gcgctcgggt	tccgcagatg	2341
	cagaggttga	ggtggctgcg	ggactggaag	tcatcgggca	gaggtctcac	agcagccagt	2401
	aagtgaacag	ctggactcgg	gctgcctggg	cggcagggag	aagcgggcag	gggaagggtc	2461
	agcagaggag	cgaggcccca	gaggagccct	gggtgaggag	acagccaagg	gctctgttcc	2521
	ctttcctgga	ctcggcttcc	acaggccctg	acctgcctcc	cccaccctcc	ggtcctgccc	2581
25	ctgtgcctgg	cagcagcccc	acctgtgtga	catcccagca	cacccccctc	ctccttgcaa	2641
	aggagaaggg	agcggcctag	gggaggccag	gggcccacct	gggctggggc	tgtggagagg	2701
	gagtggctgg	gacgggagga	aaaagagaga	cggagattag	atggaagaag	agggaatttc	2761
	agacaaaattg	ccagagatgc	agtcagagag	actgactgag	agacacaaaag	atagaaggaa	2821
	ttagagaaag	ggccacacag	agccagacag	agagagaaga	gtggagatgg	agacagggac	2881
30	gaggacagag	aaaggcagac	agacacatag	ggacagaaag	agaaaaatca	cacaaagtca	2941
	gaattactga	atgacaggga	atgacacata	gaacgagaca	cagattcaga	gactcagggc	3001
	agggaaagga	aggctgcaga	cagacagaca	gacagaggga	ggctgagaca	cagggagaag	3061
	aggggcttgg	agaggtggca	caggcaggca	gccagtgcct	cagaggcctc	cggggagggc	3121
	cctcacacac	accccgcctc	ggggcattaa	ggcagggtct	ggaggccagt	catcctgggc	3181
35	ccgcccaggg	ccgccccctc	gccagccgcg	ctgcctgggt	cctggcacct	ggcgctccaa	3241
	cccagcctac	ctgctgtagc	tgccgccact	gccgtctccg	ccgccaactg	gccccagag	3301
	cccagcccc	agagcctgtg	agtcaggag	gaaagggaag	ctgccccctc	ccgtccaggt	3361
	gtcagccctc	cccaaggaca	cctgtcccac	tcgggcaccc	atttctccct	ctgctctgtc	3421
	cttctctgct	tgggtggggg	ttcctggcct	ctctctacac	ctctcacctc	cgatggctgt	3481
40	ccgcagcctc	agttacctct	aatctccatg	gcttcagctg	ctgagctggc	cctctgtctc	3541
	cacccccgct	ggccagggca	gcggagggca	ctggccctcc	cctcgaccag	ccccgccag	3601
	ctttgtcttg	ctgtccttca	aaagggcagg	ggtttggcgg	acagggtctc	agcaagccgg	3661
	gtgatggggg	tcccagacat	tgtctggggc	tgagccccct	actccccctc	agcagacctc	3721
	aaaggctcca	tatcgctctg	ctgcgaagac	aatgaaaaag	gggtggctac	ggaacggtgt	3781
45	ctgggtcccc	ttgtccttcc	accccaagct	gctggggcct	ggccagctct	caaggcaaga	3841
	aggaaaacat	cctctgacat	gtgccgggga	ggtcccatgg	ctgacttgaa	cagggccgaa	3901
	ccatggcttg	acagctcaaa	gcccctccca	acgacttcca	catggttctt	ggtatctcgg	3961
	aagcttctag	ctgtgaccag	gccctctcca	aggccaccct	agacacctaa	gatataat	4021
	aagtgttttg	agatctgagt	gctgtgagaa	acaggggatt	tccccacctc	tgtttctccc	4081
50	aagtggggg	cgggagcagg	tgagggagag	aggagagggc	atgagccagc	ccccccctcc	4141
	cgatttcccc	gtaaaagtgat	gcggcccat	gtccctcctt	gttcccagag	gaacctgggg	4201
	cccgctcctc	ccccctccag	gccatgagga	ttctgcagtt	aatctgtgct	gctctggcaa	4261
	caggtacgca	ggggatgggg	gcagggcagg	atcctccctc	ttgaatctct	gggatccctc	4321
	aacctctctg	gtctggacag	tgacagggct	gattccaaat	tacagaacaa	cccataaggc	4381
55	acctgaactg	gagcagtggg	catgaggggc	tggtgcccct	tctagataat	ccctttaaat	4441
	gccaaaaggag	gagaggtcaa	gggggtcgta	aaggggtccc	tggaagggtc	gaggaagctg	4501
	gagttggggg	agcagtcact	caaagcggcc	aggacagggg	ctactgacca	accagtatgg	4561
	aagtatttcc	tttttttttt	ttcccagaga	caaagtcttg	ctctattgtc	caggctggag	4621
	tgccgtgggtg	ccaacacggc	tcactgcagt	cttgacttcc	cgggcttaag	tgatccttaa	4681

	gccatctcag	cttccccggt	agctgggacc	acaggcacct	gccaccaage	caggctaatt	4741
	gtttaattgt	ttgtagagat	gggggaggag	gtctcactat	gtttgcctag	gctgatctag	4801
	aactcctggg	ctcaagtaat	cctccacact	tagcctctca	aagtgcctgg	attacaggca	4861
	tgagccactg	catttgacct	tatggaagta	ttttcatcct	ttaataccgc	acccagcat	4921
5	ccagggcaac	ccagagggac	accagaccag	ggcccagacc	acccactctc	tttctctcct	4981
	ccccaccccc	attttctggga	gtcctcctgg	tctaccacct	ctccttctcg	agcccttctt	5041
	tttgctctca	ccccctccag	ggcttgtagg	gggagagacc	aggatcatca	aggggttcga	5101
	gtgcaagcct	cactcccagc	cctggcaggc	agccctgttc	gagaagacgc	ggctactctg	5161
	tggggcgacg	ctcatcgccc	ccagatggct	cctgacagca	gcccactgcc	tcaagccgtg	5221
10	gggtcggggg	ctggggcggt	gccggggtgg	ggggctggga	atggggagat	ggatggagag	5281
	aagctcaggg	ataggggtgc	tggttaaggg	attagagatg	gggatgggta	gtgtcagcaa	5341
	gggtgatggg	ctcgagttgg	tattgaaggt	gggggatga	atggggttgg	gatggggcta	5401
	tggtcgggaa	gggggcttcg	gtgggagacg	tggaagaggt	tggaagcaga	gcgatgtttc	5461
	ttcatcctca	aaggtgtcac	tcacctctcc	caccatgttc	tcccccgacc	tttctcctc	5521
15	caactactgt	ctctcccacc	tcagccgcta	catagtccac	ctggggcagc	acaacctcca	5581
	gaaggaggag	ggctgtgagc	agaccgggac	agccactgag	tccttcccc	accccggtt	5641
	caacaacagc	ctcccccaaca	aagaccaccg	caatgacatc	atgctggtga	agatggcatc	5701
	gccaagtctcc	atcacctggg	ctgtgcgacc	cctcaccttc	tcctcacgct	gtgtcactgc	5761
	tgggaccagc	tgccctcattt	ccggctgggg	cagcacgttc	agccccagc	gtaggagac	5821
20	cagaggggaa	cctggcaggg	gggtgtgagg	agggagtggg	caggattgtg	gaagggttca	5881
	gggcatcaga	gatgcggttc	acagtgcaga	tgtgggataa	gttgagagga	tgtgtggaaa	5941
	acgtcaggat	aggggggtgg	ggacaaaagt	tggggccttg	gagtcagacg	gacgggatat	6001
	gcaatcatac	atccataacc	tcctggttgt	aagaccttag	gcaagcagct	tcacctctct	6061
	gaatcttgat	tttcttctct	ataaaatgag	aatgattata	ccacctgttc	aggattggat	6121
25	tagagataat	gtatatcaag	caactgacat	aaatcattta	ttggatagca	ggctgggcac	6181
	cgtggctcac	gcctgtaatc	ccagcacttt	gggaggccga	ggtgggaaga	tcacctgagg	6241
	tcaggacttt	gataccagcc	tgccaacgt	ggtgaaatcc	catctctact	aaaaatgtga	6301
	aaattagttg	ggcgtggttg	tgtgcgcctg	taatcccagc	tactcgggag	gttgaggcag	6361
	gagaatcgct	taaaactggg	agacggaggt	tgcaatgagc	caagatcacg	ccactgcact	6421
30	ccagcctggg	caacagagca	agactctgtc	tcgaaaaaaa	aaaaaaaaaa	gctggatagc	6481
	attgctgttg	ctattgttac	aagaagagag	gtgagttggc	tgctgtctaa	gacagggtat	6541
	cccccagggg	cgggatcaca	gcaagcactg	cattagggga	ggtggcaggg	ggctcattcc	6601
	cacagccctt	cacgctgttt	ccacagtacg	cctgcctcac	accttgcgat	gcgccaacat	6661
	caccatcatt	gagcaccaga	agtgtgagaa	cgcctacccc	ggcaacatca	cagacaccat	6721
35	ggtgtgtgcc	agcgtgcagg	aagggggcaa	ggactcctgc	caggtcagtg	tggtctccaa	6781
	ccacagcccc	atccccatcc	ccagcttcaa	tgacatcttt	accgacatcc	acaatttcat	6841
	ccccaacctc	aaccgcgcca	cccttgcaac	tcccaatcca	tctcttcccc	tggtcccggt	6901
	tctgacctca	gcacaaactt	cagctccatc	cccgtttcca	caccatttcc	agctccaacc	6961
	atccccaaac	tcgtttttga	gcctaaccct	atcctttatc	ccaccataaa	tcccagcttt	7021
40	atcgctaaac	ctatcacctt	tcccagtgcc	taccatcctt	gtctcggccc	cactcctaag	7081
	caccgtcccc	acctcctccc	tggttaacac	catgctcaac	gctttctctg	accgacattc	7141
	tctctccccg	tgcccagggt	gactccgggg	gcctctctgt	ctgtaaccag	tctcttcaag	7201
	gcattatctc	ctggggccag	gatccgtgtg	cgatcacccc	aaagcctggg	gtctacacga	7261
	aagtctgcaa	atatgtggac	tggtatccag	agacgatgaa	gaacaattag	actggaccaca	7321
45	cccaccacag	cccatcaccc	tccatttcca	cttggtgttt	ggttcctgtt	cactctgtta	7381
	ataagaaacc	ctaagccaag	accctctacg	aacattcttt	gggcctcctg	gactacagga	7441
	gatgctgtca	cttaataaat	aacctggggg	tcgaaatcag	tgagacctgg	attcaaattc	7501
	tgctttgaaa	tattgtgact	ctgggaatga	caacacctgg	tttgttctct	gttgatatcc	7561
	cagcccccac	gacagctcct	ggccatatat	caagggtttc	ataaatattt	gctaaatgag	7621
50	tgaatctact	gagtgccttac	tatgtgctag	accctgatcc	aatggctttt	attttatttt	7681
	attttttgac	agagtctcgc	tctgtcaccc	aggctggagt	acagtgggtg	tatctctgct	7741
	cactgcaacc	tccacctcct	gggttcaagc	aattctcctg	cctcagcctc	ctgaatagct	7801
	gggattacag	gtgcctacca	ccacatccgg	ctaatttttg	tatttttttag	tagagatggg	7861
	gcttcaccat	gttgccaggg	ctggtctcga	actcctgacc	tcagatgatc	tgccctcctt	7921
55	ggcctcccaa	actcctggga	ttacagacgt	gagccaccgc	gcccgcggcg	ctttcattta	7981
	ttaattaaaa	gaaattaaat	taattaatct	atttaggaga	cagtccttgc	ctgttgccca	8041
	ggctggagtg	cagtaacaat	cacagctcac	ggcaatctca	atttctctgg	gtcaagtgat	8101
	tgctcctcct	cagcctccag	agtagctggg	actacaggca	catgccacga	agcccagcta	8161
	atttttgtat	ttttcgtaga	gacagaggtc	tcagtatgtt	gccccgggta	gtctcaaaact	8221

5 cctgggctca agcagtcctgt cctcctcagc ctccaaaagt ggtgagatta caggcatgag 8281  
tcgctgtgcc tggcctccaa gcactttcaa atgtatcaac ttaatcctca caaaaccctg 8341  
tgaggctcggg actgttttca tacctatttt atagttgaag aaacagacac agagaagcaa 8401  
agtcacttgc tcacagtcac gtggctagga gagcaaggat ctgaagcaag gcgatctctt 8461  
aattaccaag tgatgttcct ggagtaaggc tctgtttgtt tcctttcctg taaaatgctg 8521  
catgcaaaaag tataacacag taagtaaaga agtcagttag cctgcacata ctaagaccta 8581  
accaaaggag cttattgttt ttctccaact tccatgatag gtaattagat agtggagacc 8641  
tctgctggcc aatatggtag ccactaaccg cagctggctc ttccaattaa aattacataa 8701  
agccagaaat gtaactcctc tgtctcactt gttatatctc caaggctgga tagccacatg 8761  
10 tgactggtgg tggctggatt agctagtgc tataaaacat cactgcagaa agttcagctg 8821  
agcagcactg agttagatgg cctctgaaga ggatgtccca cggagagaat ccagaactca 8881  
ggatcctttt tttttttttt ctttgcgaca gagtcttgct ctgtcaccca ggctggagtg 8941  
cagtggcgtg atctcggctc actgcaactt ctgcctccca ggttcaagca attctcctgc 9001  
ctcagcctcc ctagtagctg ggactacagg cctgtgccaa catcccagc taatttttgt 9061  
15 gtcttttttag tagagatggg gtttcactat gttggccagg ctggtctcga actcctgacc